Original Article
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
N Engl J Med 1996; 335:1950-1955December 26, 1996
- Abstract
Background
Intravenous platinum-based chemotherapy is the standard primary therapy for advanced ovarian cancer. We conducted a phase 3 trial to compare the effects of intraperitoneal and intravenous cisplatin on the survival of women with previously untreated, stage III, epithelial ovarian cancer.
Methods
The patients underwent an initial exploratory laparotomy and resection of all tumor masses larger than 2 cm. Within four weeks after surgery, six courses of intravenous cyclophosphamide (600 mg per square meter of body-surface area per course) plus either intraperitoneal cisplatin (100 mg per square meter) or intravenous cisplatin (100 mg per square meter) were administered at three-week intervals.
Results
Of 654 randomized patients, 546 were eligible for the study. The estimated median survival was significantly longer in the group receiving intraperitoneal cisplatin (49 months; 95 percent confidence interval, 42 to 56) than in the group receiving intravenous cisplatin (41 months; 95 percent confidence interval, 34 to 47). The risk of death was lower in the intraperitoneal group than in the intravenous group (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P = 0.02). Moderate-to-severe tinnitus, clinical hearing loss, and neuromuscular toxic effects were significantly more frequent in the intravenous group.
Conclusions
As compared with intravenous cisplatin, intraperitoneal cisplatin significantly improves survival and has significantly fewer toxic effects in patients with stage III ovarian cancer and residual tumor masses of 2 cm or less.
Media in This Article
Figure 1
Survival of 546 Eligible Patients with Stage III Ovarian Cancer Who Were Randomly Assigned to Treatment with Intravenous or Intraperitoneal Cisplatin.Figure 2
Survival of Eligible Patients According to the Extent of Residual Disease at Enrollment.Article Activity
- Article
Ovarian cancer, the leading cause of death from gynecologic cancer in the United States, is one of the few solid tumors in which the five-year survival rate for patients has improved in recent years.1,2 Nevertheless, most women with advanced ovarian cancer die of the disease. Even those with stage III cancer and minimal residual intraperitoneal masses (<2 cm in the greatest dimension) have a median survival of only about 40 months.3,4
Standard chemotherapy for advanced ovarian cancer includes a platinum analogue (either cisplatin or carboplatin). In an attempt to maximize its activity against ovarian cancer, cisplatin has been administered directly into the peritoneal cavity in investigational studies.5 This route yields an intraperitoneal concentration of cisplatin that is 12 to 15 times greater than the plasma concentration.6,7 Some phase 2 studies have suggested that survival is prolonged in patients with small residual masses (<1 cm) who receive salvage intraperitoneal chemotherapy after initial chemotherapy and second-look surgery.8,9 The present phase 3 trial compares cisplatin administered intraperitoneally with cisplatin administered intravenously in patients with previously untreated stage III ovarian cancer and residual masses no larger than 2 cm in the greatest dimension.
Methods
Patients
Within four weeks before enrollment, patients underwent an initial exploratory laparotomy with at least bilateral salpingo-oophorectomy, total abdominal hysterectomy, omentectomy, and debulking of all tumor nodules to a size of 2 cm or less in the greatest dimension. The Southwest Oncology Group's Gynecologic Surgical Review Board reviewed the surgical results to confirm eligibility for enrollment. Only patients with a histologic diagnosis of epithelial-type ovarian cancer were eligible.
Eligible patients had stage III disease, a performance status of 0 to 2 (according to criteria established by the Southwest Oncology Group), normal blood counts, and adequate renal function (serum creatinine, <1.5 mg per deciliter [130 μmol per liter]; creatinine clearance, >40 ml per minute). All patients gave informed consent according to institutional and federal guidelines before enrollment.
Treatment Plan
Patients were randomly assigned to receive intraperitoneal cisplatin plus intravenous cyclophosphamide or intravenous cisplatin plus intravenous cyclophosphamide. The randomization procedure incorporated stratification according to the amount of residual tumor (<0.5 cm vs. >0.5 cm to 2 cm), performance status (0 or 1 vs. 2), the timing of enrollment (during vs. after surgery), and the cooperative group (Southwest Oncology Group vs. Gynecologic Oncology Group vs. Eastern Cooperative Oncology Group).
Patients in both treatment groups received cyclophosphamide (600 mg per square meter of body-surface area in 150 ml of diluent) administered in a 60-to-90-minute intravenous infusion on day 1. Patients in the intravenous group received cisplatin (100 mg per square meter in 500 to 1000 ml of normal saline) administered intravenously at a rate of 1 mg per minute, followed by at least 1 liter of normal saline with 3 g of magnesium sulfate and 40 g of mannitol over a period of one to two hours on day 1. Patients in the intraperitoneal group received cisplatin (100 mg per square meter in 2 liters of normal saline) warmed to body temperature and instilled into the peritoneal cavity as rapidly as possible. Concurrently, these patients received at least 1 liter of normal saline with 3 g of magnesium sulfate and 40 g of mannitol intravenously.
Courses of cyclophosphamide and cisplatin were repeated every three weeks for a total of six cycles, provided the serum creatinine concentration was less than or equal to 1.9 mg per deciliter (170 μmol per liter), the white-cell count was higher than 3000 per cubic millimeter, and the platelet count was higher than 100,000 per cubic millimeter. Therapy could be delayed for a maximum of two weeks to allow for the resolution of toxic effects. Cisplatin was permanently discontinued and the dose of cyclophosphamide increased to 1 g per square meter (in the absence of grade 3 or 4 myelosuppression) if peripheral neuropathy of grade 2 or higher developed or the serum creatinine concentration rose above 1.9 mg per deciliter. Therapy was discontinued altogether if the serum creatinine level remained higher than 1.9 mg per deciliter for eight weeks.
Clinical and Pathological Assessments
At base line and after six courses of therapy, a physical examination was performed, with a complete blood count, serum CA-125 and blood chemical measurements, and chest radiography. In addition, before each cycle, a physical examination was performed, with a complete blood count and measurement of serum CA-125 and creatinine concentrations. Blood chemical measurements were performed at the start of every other course. At the completion of therapy, patients without clinical evidence of ovarian cancer (excluding an elevated serum CA-125 value) underwent a second-look laparotomy to determine whether there had been a pathological response.
A complete pathological response was defined as no pathological evidence of disease on second-look surgery and biopsy of the upper abdomen and the para-aortic and retroperitoneal lymph nodes, as well as any other site previously involved with tumor.
Statistical Analysis
In the original study design (before the protocol was amended to increase enrollment), it was assumed that 215 eligible patients would be randomly assigned to each treatment group. At a two-sided P value of 0.05, with the use of a Pearson chi-square approximation, the estimated power was 0.85 to detect a difference of 55 percent versus 40 percent in pathological-response rates in the intraperitoneal and intravenous groups, respectively. The power was 0.93 (two-sided log-rank test, α = 0.05) to detect a difference if the underlying risk of death (hazard ratio) in the intraperitoneal group, as compared with the intravenous group, was 0.67. Survival was defined as the time from randomization to death from any cause.
Provisions for subgroup analysis were not included in the original study design. During the study, however, a consensus emerged among gynecologic oncologists that the patients most likely to benefit from intraperitoneal chemotherapy were those with a tumor mass that was no larger than 0.5 cm in the greatest dimension. Therefore, in January 1991, with no knowledge of subgroup data, we extended accrual for an additional year to achieve a sufficiently large sample for a separate analysis of data from patients with residual tumors that were no larger than 0.5 cm. All previously eligible patients were included in the extended sample, which was planned to include 560 eligible patients overall and 390 eligible patients with residual tumors no larger than 0.5 cm. In the analysis of this subgroup, if the hazard ratio was 0.67 for the patients receiving intraperitoneal treatment, the power to detect a difference was 0.88.
The treatment group, size of residual tumor (microscopical vs. <0.5 cm vs. >0.5 cm to 2 cm), age, performance status (0 or 1 vs. 2), race (white vs. other), tumor type (clear cell or mucinous vs. other), tumor grade, participating group (Southwest Oncology Group vs. Gynecologic Oncology Group vs. Eastern Cooperative Oncology Group), and timing of enrollment (during vs. after surgery) were included as covariates in Cox regression analyses.10 Two-sided Fisher's exact tests were used for comparisons of toxic effects in the two treatment groups. All eligible patients who received chemotherapy were included in the analysis of toxicity.
Results
Patients
Between June 1986 and July 1992, 654 women were randomly assigned to a study group: 295 from the Southwest Oncology Group, 298 from the Gynecologic Oncology Group, and 61 from the Eastern Cooperative Oncology Group. A total of 108 patients were ineligible (52 in the intravenous group and 56 in the intraperitoneal group) for the following reasons: inadequate surgery (in 54), pathological findings that did not meet the study criteria (31), insufficient documentation (20), and miscellaneous clinical factors that did not meet the study criteria (3). Table 1Table 1
Characteristics of 546 Eligible Patients with Stage III Ovarian Cancer Who Were Assigned to Treatment with Intravenous or Intraperitoneal Cisplatin. shows the characteristics of the eligible patients. There were no significant differences between the study groups with respect to important prognostic factors.Of the 279 eligible patients in the intravenous group, 2 died before treatment, and 1 refused treatment after randomization. There were 20 major protocol violations among the 267 eligible patients in the intraperitoneal group: 3 patients died before treatment was started, 6 withdrew consent after randomization, 8 did not receive the assigned treatment for other reasons (5 because of complications related to intraperitoneal catheterization and 3 because of errors by the local pathologist), 2 received treatment for only one day, and 1 erroneously received intravenous carboplatin during cycles 2 through 6. All 546 eligible patients were included in the efficacy analyses (according to the intention-to-treat principle), regardless of whether they completed the assigned treatment. The 20 patients in both groups who did not receive any treatment were excluded from the toxicity analysis.
Intensity of Cisplatin Dose
In both the intravenous and intraperitoneal groups, 58 percent of all eligible patients completed six courses of cisplatin therapy (Table 2Table 2
Percentages of Eligible Patients Receiving Cisplatin and the Dose Received during Each Course of Treatment.). Among these patients, the average proportion of the initial cisplatin dose administered during cycle 6 (the course with the maximal dose reduction) was 96 percent in the intravenous group and 97 percent in the intraperitoneal group. Cisplatin was discontinued because of toxic effects (with a concomitant increase in the cyclophosphamide dose) in 40 patients in the intravenous group and 22 in the intraperitoneal group.Complete Pathological Responses
Of the 546 eligible patients, 20 never received any study treatment, 81 did not complete therapy, and 45 had tumors that progressed before the completion of therapy. Second-look surgery was not required in these patients. In 103 of the remaining 400 patients, surgery was contraindicated or the patient refused it (70 patients), or the procedure was performed but deemed inadequate by the Gynecologic Surgical Review Board (33). Because of the bias associated with this group of 103 patients who had no clinical evidence of disease at the completion of therapy but did not undergo second-look surgery or had inadequate surgery, the rates of pathological responses are given without statistical comparisons.
A total of 297 patients with no clinical evidence of disease at the end of chemotherapy underwent adequate second-look surgery. The rate of complete pathological responses was 36 percent in the intravenous group (complete responses in 57 of 158 patients) and 47 percent in the intraperitoneal group (complete responses in 66 of 139).
Survival
All eligible patients were included in the primary analysis regardless of whether they completed the assigned treatment. Covariates associated with improved survival included the absence of gross disease at enrollment (P<0.001), a younger age (P<0.001), a type of tumor other than clear cell or mucinous (P<0.001), and enrollment after surgery (P<0.001). The final Cox model included these four factors and performance status (which was retained in the model because of its established prognostic importance).
The results after adjustment for these five factors are shown in Table 3Table 3
Survival of All Eligible Patients, Eligible Patients with Minimal Residual Disease, and All Randomized Patients., along with unadjusted median survival in the two groups. The hazard ratio for the risk of death in the intraperitoneal group, as compared with the intravenous group, was 0.76 (95 percent confidence interval, 0.61 to 0.96; P = 0.02). The median survival was 41 months (95 percent confidence interval, 34 to 47) in the intravenous group and 49 months (95 percent confidence interval, 42 to 56) in the intraperitoneal group (Figure 1Figure 1Survival of 546 Eligible Patients with Stage III Ovarian Cancer Who Were Randomly Assigned to Treatment with Intravenous or Intraperitoneal Cisplatin.).Figure 2Figure 2
Survival of Eligible Patients According to the Extent of Residual Disease at Enrollment. shows the survival curves for all eligible patients according to the extent of residual intraperitoneal disease. The effect of the treatment (intravenous or intraperitoneal cisplatin) was not influenced by the extent of residual disease (P = 0.93 for the interaction of treatment and residual disease). Table 3 shows the results of a separate analysis for the subgroup of patients with residual tumors no larger than 0.5 cm. The analysis was repeated for all 654 randomized patients, including those who were ineligible. The results were equivalent to those of the primary analysis (Table 3).Toxic Effects
Two treatment-related deaths occurred in the intraperitoneal group. One patient died of respiratory failure of unknown cause 41 days after the second cycle of chemotherapy (blood counts were adequate at the time of death). The second patient died of bronchopneumonia during a period of chemotherapy-associated leukopenia 13 days after the third cycle. No treatment-related deaths occurred in the intravenous group.
Significantly more patients in the intravenous group than in the intraperitoneal group had grade 3 or higher granulocytopenia (P = 0.002) and leukopenia (P = 0.04) (Table 4Table 4
Frequency of Hematologic Toxic Effects (>Grade 3) during Any Course of Treatment.). Table 5Table 5
Frequency of Other Toxic Effects (>Grade 2) during Any Course of Treatment. shows the frequency of other toxic effects (grade 2 or higher) during any treatment cycle. Moderate-to-severe tinnitus and hearing loss were more frequent in patients receiving intravenous cisplatin than in those receiving intraperitoneal cisplatin. In addition, significantly more patients in the intravenous group had grade 2 or 3 neuromuscular toxic effects at the completion of chemotherapy (25 percent, vs. 15 percent in the intraperitoneal group; P = 0.02).As expected, abdominal pain of grade 2 or higher was more common in the intraperitoneal group (P<0.001); however, the pain usually resolved within 24 hours and was controlled with nonopioid or only weak opioid drugs. One patient had grade 4 abdominal pain. Transient dyspnea was infrequent but occurred in a significantly larger proportion of patients in the intraperitoneal group (3 percent, vs. 0.4 percent in the intravenous group; P = 0.002). In the patients receiving intraperitoneal cisplatin, dyspnea probably resulted from compression of the base of the lung by the fluid-filled intraperitoneal cavity.
Discussion
In this study we compared intraperitoneal with intravenous cisplatin in women with advanced ovarian cancer. All the patients had undergone debulking surgery and received intravenous cyclophosphamide concomitantly with the cisplatin. The median survival of the patients treated intraperitoneally was 8 months longer than that of the patients given intravenous cisplatin (49 vs. 41 months), and the hazard ratio in the intraperitoneal group was 0.76 (P = 0.02). These results represent a 20 percent improvement in median survival and a 24 percent reduction in the risk of death during the entire follow-up period among the eligible patients in the intraperitoneal group.
Neutropenia, tinnitus, hearing loss, and neuromuscular toxic effects were significantly less frequent in the intraperitoneal group than in the intravenous group. Abdominal pain was more common in the intraperitoneal group, but in most cases it was transient and not severe (i.e., grade 3 or higher in only 5 percent of the patients).
Previous reports have summarized the toxic effects of intraperitoneal cisplatin at doses ranging from 50 to 100 mg per square meter.11-13 Chronic, low-grade inflammation from repeated intraperitoneal administration may cause mild-to-severe abdominal pain and intraabdominal adhesions. These reports have generally focused on patients who had undergone two exploratory laparotomies before the administration of intraperitoneal cisplatin. In our study, all the patients had undergone only one definitive exploratory laparotomy within four weeks before the start of chemotherapy. Thus, our patients were probably less susceptible to the local toxic effects of intraperitoneal cisplatin.
Howell et al. reported that after second-line therapy with intraperitoneal cisplatin, rates of surgically established complete responses were significantly higher among patients with smaller residual intraperitoneal tumor masses (<0.5 cm) than among those with larger masses (>0.5 cm to 2 cm).8 Consistent with this finding was the 80 percent rate of a complete pathological response among our patients with no gross residual disease who received intraperitoneal cisplatin (32 of 40 patients), as compared with a rate of 56 percent among those with no gross residual disease who received intravenous cisplatin (24 of 43). Such results reflect the fact that the penetration of intraperitoneal cisplatin is limited to a depth of 0.1 to 1 mm from the surface of the peritoneal tumor.14
We found that intraperitoneal cisplatin was associated with a longer survival than was intravenous cisplatin, whether residual intraperitoneal tumor masses were 0.5 cm or less or more than 0.5 cm in the greatest dimension. We do not know the reason for this result, but several explanations are possible. All previous investigations of intraperitoneal cisplatin therapy have been phase 2 studies, which included mainly patients who had already received intravenous cisplatin. Our patients had never before received chemotherapy, and their tumors may therefore have been highly sensitive to cisplatin. Moreover, the precision in measuring intraperitoneal tumor masses during an initial exploratory laparotomy is limited, and the total volume of the mass may have more prognostic value than the maximal dimension.
The combination of intravenous paclitaxel plus intraperitoneal cisplatin may prove to be more effective than intravenous cyclophosphamide plus intraperitoneal cisplatin in patients with stage III ovarian cancer and minimal residual disease. The Gynecologic Oncology Group recently reported that paclitaxel plus cisplatin significantly increased survival (median, 38 months, vs. 24 months with cyclophosphamide plus cisplatin) when administered as primary chemotherapy in women with incompletely resected stage III or IV ovarian cancer.15 Ongoing phase 3 studies by the Gynecologic Oncology Group and the Southwest Oncology Group will further define the role of intraperitoneal cisplatin (and intravenous paclitaxel) in the treatment of stage III ovarian cancer that has been optimally resected.
Supported in part by grants from the National Cancer Institute (CA38926, CA32102, CA45450, CA04920, CA42028, CA46441, CA45560, CA13612, CA20319, CA35119, CA35090, CA35281, CA58686, CA28862, CA35431, CA35200, CA45377, CA58861, CA45807, CA35261, CA12644, CA35192, CA37981, CA42777, CA16385, CA12213, CA35128, CA04919, CA35178, CA35176, CA35262, CA32734, CA46282, and CA58415) and Bristol-Myers Squibb.
We are indebted to Drs. Renzo Canetta and Mace Rothenberg for scientific advice; to the individual investigators for their participation and support (especially Drs. Ronald Alvarez, Albert Bonebrake, Eric Jenison, William Creasman, Nicola Spirtos, Matthew Burrell, and Mark Crozier); to Dava Garcia for assistance with study coordination and manuscript preparation; to Janet O'Sullivan, M.S., for assistance with the statistical analysis; to Dana Sparks, M.A.T., for protocol coordination; to Janet Quade, Nancy Mason-Liddil, and Dianna Garcia for assistance with data management; and to Lois Loescher, R.N., M.S., for editorial assistance.
Source Information
From the University of Arizona, Tucson (D.S.A.); the Southwest Oncology Group Statistical Center, Seattle (P.Y.L.); the University of Texas Medical Branch at Galveston, Galveston (E.V.H.); Ohio State University Health Center, Columbus (R.O.); the Gynecologic Oncology Group, Philadelphia (S.D.W., D.L.C.-P., B.D., M.D.A., W.J.H.); Indiana University School of Medicine, Indianapolis (S.D.W.); the Eastern Cooperative Oncology Group, Boston (J.A.Y.); Cancer Care Associates, Tulsa, Okla. (J.A.Y.); Atlanta Regional Community Clinical Oncology Program, Atlanta (E.W.F.); Wayne State University Medical Center, Detroit (V.K.M.); and the University of Rochester Medical School, Rochester, N.Y. (B.D.).
Address reprint requests to Dr. Alberts at the Southwest Oncology Group (SWOG-8501), Operations Office, 14980 Omicron Dr., San Antonio, TX 78245-3217.
- References
References
1
Wingo PA ,Tong T ,Bolden S . Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30[Erratum, CA Cancer J Clin 1995;45:127-8.]
CrossRef | Web of Science | Medline2
Miller BA, Ries LAG, Hankey BF, et al., eds. SEER cancer statistics review: 1973-1990. Bethesda, Md.: National Cancer Institute, 1993. (NIH publication no. 93-2789.)
3
Neijt JP ,ten Bokkel Huinink WW ,van der Burg MEL , et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5:1157-1168
Web of Science | Medline4
Omura GA ,Bundy BN ,Berek JS ,Curry S ,Delgado G ,Mortel R . Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:457-465
Web of Science | Medline5
Dedrick RL ,Myers CE ,Bungay PM ,DeVita VT Jr . Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-11
Medline6
Howell SB ,Pfeifle CL ,Wung WE , et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-851
Web of Science | Medline7
Goel R ,Cleary SM ,Horton C , et al. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 1989;81:1552-1560
CrossRef | Web of Science | Medline8
Howell SB ,Zimm S ,Markman M , et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987;5:1607-1612
Web of Science | Medline9
Kirmani S ,Lucas WE ,Kim S , et al. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol 1991;9:649-657
Web of Science | Medline10
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22011
Piccart MJ ,Speyer JL ,Markman M , et al. Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 1985;12:Suppl 4:90-96
Web of Science | Medline12
Markman M . Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986;13:219-242
CrossRef | Web of Science | Medline13
Markman M. Intraperitoneal chemotherapy for gynecologic malignancies. In: Deppe G, ed. Chemotherapy of gynecologic cancer. 2nd ed. New York: Alan R. Liss, 1990:375-90.
14
Los G ,Mutsaers PHA ,van der Vijgh WJF ,Baldew GS ,de Graaf PW ,McVie JG . Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380-3384
Web of Science | Medline15
McGuire WP ,Hoskins WJ ,Brady MF , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6
Full Text | Web of Science | Medline
- Citing Articles (367)
Citing Articles
1
William R. Robinson, Julie Beyer, Stephen Griffin, Paiyarut Kanjanavaikoon. (2012) Extraperitoneal Metastases From Recurrent Ovarian Cancer. International Journal of Gynecological Cancer 22:1, 43-46
CrossRef2
Perren, Timothy J., Swart, Ann Marie, Pfisterer, Jacobus, Ledermann, Jonathan A., Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S., Beale, Philip, Cervantes, Andrés, Kurzeder, Christian, Bois, Andreas du, Sehouli, Jalid, Kimmig, Rainer, Stähle, Anne, Collinson, Fiona, Essapen, Sharadah, Gourley, Charlie, Lortholary, Alain, Selle, Frédéric, Mirza, Mansoor R., Leminen, Arto, Plante, Marie, Stark, Dan, Qian, Wendi, Parmar, Mahesh K.B., Oza, Amit M., . (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. New England Journal of Medicine 365:26, 2484-2496
Full Text3
B Royer, E Kalbacher, S Onteniente, V Jullien, D Montange, S Piedoux, A Thiery-Vuillemin, D Delroeux, S Pili-Floury, E Guardiola, M Combe, P Muret, V Nerich, B Heyd, B Chauffert, J-P Kantelip, X Pivot. (2011) Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study. British Journal of Cancer
CrossRef4
M. A. Bookman. (2011) Update of randomized trials in first-line treatment. Annals of Oncology 22:Suppl 8, Viii52-viii60
CrossRef5
Shoji Nagao, Norihiro Iwasa, Akira Kurosaki, Tadaaki Nishikawa, Rie Ohishi, Kosei Hasegawa, Tomoko Goto, Keiichi Fujiwara. (2011) Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma. International Journal of Gynecological Cancer1
CrossRef6
Natalie Gould, Michael W. Sill, Robert S. Mannel, P.H. Thaker, Paul DiSilvestro, Steve Waggoner, S. Diane Yamada, Deborah K. Armstrong, Lari Wenzel, Helen Huang, Paula M. Fracasso, Joan L. Walker. (2011) A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology
CrossRef7
N. Bakrin, O. Glehen, F. Golfier. (2011) CHIP et cancer de l’ovaire : en finir avec les préjugés. Gynécologie Obstétrique & Fertilité
CrossRef8
Gaurav Bajaj, Mi Ran Kim, Sulma I. Mohammed, Yoon Yeo. (2011) Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. Journal of Controlled Release
CrossRef9
Kenneth Jaaback, Nick Johnson, Theresa A Lawrie, Kenneth Jaaback. 2011. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. .
CrossRef10
Don S. Dizon, Michael W. Sill, Natalie Gould, Stephen C. Rubin, S. Diane Yamada, Robert L. DeBernardo, Robert S. Mannel, Eric L. Eisenhauer, Linda R. Duska, Paula M. Fracasso. (2011) Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study. Gynecologic Oncology 123:2, 182-186
CrossRef11
Melissa S. Henretta, Curtis L. Anderson, J. Fritz Angle, Linda R. Duska. (2011) It's not just for laparoscopy anymore: Use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters. Gynecologic Oncology 123:2, 342-345
CrossRef12
Manjunath Laxmayya Ramarajapalli, Nalini Gurunath Kilara, Murali Subramanyam, Nitin A. R. Rao. (2011) Technique of Intraperitoneal Chemotherapy Using Veress Needle in Patients With Ovarian Cancer. International Journal of Gynecological Cancer 21:8, 1388-1390
CrossRef13
Payam Zahedi, James Stewart, Raquel De Souza, Micheline Piquette-Miller, Christine Allen. (2011) An Injectable Depot System for Sustained Intraperitoneal Chemotherapy of Ovarian Cancer Results in Favorable Drug Distribution at the Whole Body, Peritoneal and Intratumoral Levels. Journal of Controlled Release
CrossRef14
Malgorzata E. Skaznik-Wikiel, Jamie L. Lesnock, William C. McBee, Sushil Beriwal, Kristin K. Zorn, Scott D. Richard, Thomas C. Krivak, Robert P. Edwards. (2011) Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient Outcomes. International Journal of Gynecological Cancer1
CrossRef15
Craig R. Greben, Greg E. Goldstein, John Lovecchio, Veena John, Daniel Putterman, Drew Caplin, Eric J. Gandras. (2011) Percutaneous Insertion of Peritoneal Ports. International Journal of Gynecological Cancer1
CrossRef16
P.A. Cascales, J. Gil, P.J. Galindo, F. Machado, I.M. Martinez Frutos, P. Parrilla Paricio. (2011) Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. European Journal of Obstetrics & Gynecology and Reproductive Biology 158:2, 361-362
CrossRef17
Christina L. Kushnir, Aimee C. Fleury, David F. Silver, Nick M. Spirtos. (2011) Intraperitoneal Catheter Placement: The “Hammock” Technique. Clinical Ovarian Cancer
CrossRef18
Edward J. Tanner, Destin R. Black, Oliver Zivanovic, Siobhan M. Kehoe, Fanny Dao, Jason A. Konner, Richard R. Barakat, Stuart M. Lichtman, Douglas A. Levine. (2011) Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecologic Oncology
CrossRef19
CW Helm. (2011) Ports and complications for intraperitoneal chemotherapy delivery. BJOG: An International Journal of Obstetrics & Gynaecologyno-no
CrossRef20
Ginger J. Gardner, Raymond E. Baser, Mark F. Brady, Robert E. Bristow, Maurie Markman, David Spriggs, Howard T. Thaler. (2011) CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: A gynecologic oncology group study. Gynecologic Oncology
CrossRef21
Benedetta Isacchi, Silvia Arrigucci, Giancarlo la Marca, Maria Camilla Bergonzi, Maria Giuliana Vannucchi, Andrea Novelli, Anna Rita Bilia. (2011) Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. Journal of Liposome Research 21:3, 237-244
CrossRef22
Jo Marie Tran Janco, Michele R. Hacker, Panagiotis A. Konstantinopoulos, Stephen A. Cannistra, Christopher S. Awtrey. (2011) Laparoscopic Intraperitoneal Port Placement for Optimally Cytoreduced Advanced Ovarian Cancer. Journal of Minimally Invasive Gynecology 18:5, 629-633
CrossRef23
Lisa M. Landrum, Johnny Hyde, Robert S. Mannel, D. Scott McMeekin, Kathleen N. Moore, Joan L. Walker. (2011) Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecologic Oncology 122:3, 527-531
CrossRef24
Jamie L. Lesnock, Coreen Farris, Thomas C. Krivak, Kenneth J. Smith, Maurie Markman. (2011) Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecologic Oncology 122:3, 473-478
CrossRef25
Pierre-Emmanuel Colombo, Mahfoud Boustta, Sylvain Poujol, Marta Jarlier, Françoise Bressolle, Isabelle Teulon, Maha-Zohra Ladjemi, Frederic Pinguet, Philippe Rouanet, Michel Vert. (2011) Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: Experimental study in a murine model of ovarian cancer. Gynecologic Oncology 122:3, 632-640
CrossRef26
Michael A. Bookman. (2011) First line therapy: have we made any improvement?. European Journal of Cancer 47, S93-S103
CrossRef27
Santiago Domingo, Marta Gurrea, Antonio Pellicer. (2011) How to improve the optimal cytoreductive surgery in advanced ovarian carcinoma. Gynecological Surgery 8:3, 289-298
CrossRef28
Ahmed Elattar, Andrew Bryant, Brett A Winter-Roach, Mohamed Hatem, Raj Naik, Ahmed Elattar. 2011. Optimal primary surgical treatment for advanced epithelial ovarian cancer. .
CrossRef29
Anna Fagotti, Barbara Costantini, Giuseppe Vizzielli, Federica Perelli, Alfredo Ercoli, Valerio Gallotta, Giovanni Scambia, Francesco Fanfani. (2011) HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome. Gynecologic Oncology 122:2, 221-225
CrossRef30
Marcello Deraco, Shigeki Kusamura, Salvatore Virzì, Francesco Puccio, Antonio Macrì, Ciro Famulari, Massimiliano Solazzo, Serena Bonomi, Domenico Rosario Iusco, Dario Baratti. (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial. Gynecologic Oncology 122:2, 215-220
CrossRef31
Eleni Andreopoulou, Thomas Chen, Leonard Liebes, John Curtin, Stephanie Blank, Robert Wallach, Howard Hochster, Franco Muggia. (2011) Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer Chemotherapy and Pharmacology 68:2, 457-463
CrossRef32
Ana Oaknin, Desamparado Roda, Antonio González-Martín, Luis Chiva, Jesús García-Donas, Ana de Juan, Andrés Redondo, Sergio Martínez, Yolanda García, Sílvia Catot, Jordi Ponce, J.M. del Campo, Andrés Cervantes, Andrés Poveda. (2011) Feasibility of a Modified Outpatient Regimen of Intravenous/Intraperitoneal Chemotherapy in Optimally Debulked Stage III Ovarian Cancer Patients. International Journal of Gynecological Cancer 21:6, 1048-1055
CrossRef33
Paul Zarogoulidis, Ellada Eleftheriadou, Iordanis Sapardanis, Vasiliki Zarogoulidou, Helliel Lithoxopoulou, Theodoros Kontakiotis, Nikolaos Karamanos, George Zachariadis, Maria Mabroudi, Athanasios Zisimopoulos, Kostantinos Zarogoulidis. (2011) Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Investigational New Drugs
CrossRef34
Tien Le, Hassan Latifah, Lynne Jolicoeur, Wylam Faught, Johanne Weberpals, Laura Hopkins, Michael Fung-Kee-Fung. (2011) Comparative Study of Grade 3/4 Toxicity Associated With Intraperitoneal Chemotherapy Administered After Primary Versus Interval Surgical Debulking in Ovarian Cancer. International Journal of Gynecological Cancer 21:5, 811-815
CrossRef35
Francisco C. Muñoz-Casares, Sebastián Rufián, Álvaro Arjona-Sánchez, María J. Rubio, Rafael Díaz, Ángela Casado, Álvaro Naranjo, Carlos J. Díaz-Iglesias, Rosa Ortega, María C. Muñoz-Villanueva, Jordi Muntané, Enrique Aranda. (2011) Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study. Cancer Chemotherapy and Pharmacology 68:1, 267-274
CrossRef36
Margarett C. Ellison. 2011. Pelvic Masses and Ovarian Carcinoma. , 361-376.
CrossRef37
T. Le, H. Latifah, L. Jolicoeur, J. Weberpals, W. Faught, L. Hopkins, M. Fung Kee Fung. (2011) Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?. Gynecologic Oncology 121:3, 451-454
CrossRef38
Danijela Jelovac, Deborah K. Armstrong. (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA: A Cancer Journal for Clinicians 61:3, 183-203
CrossRef39
Mark A. Morgan, Michael W. Sill, Keiichi Fujiwara, Benjamin Greer, Stephen C. Rubin, Koen DeGeest, S. Diane Yamada, Steven Waggoner, Robert L. Coleman, Joan L. Walker, Robert S. Mannel. (2011) A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology 121:2, 264-268
CrossRef40
David Silver, Nadim Bou Zgheib. (2011) Outpatient Intraperitoneal Chemotherapy for All Stages of Ovarian, Fallopian Tube, and Peritoneal Cancers: A Pilot Study. Clinical Ovarian Cancer
CrossRef41
S. J. Dawson, R. J. Hicks, V. Johnston, D. Allen, T. Jobling, M. Quinn, D. Rischin. (2011) Intraperitoneal distribution imaging in ovarian cancer patients. Internal Medicine Journal 41:2, 167-171
CrossRef42
K. Fujiwara, E. Aotani, T. Hamano, S. Nagao, H. Yoshikawa, T. Sugiyama, J. Kigawa, D. Aoki, N. Katsumata, M. Takeuchi, M. Suzuki. (2011) A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. Japanese Journal of Clinical Oncology 41:2, 278-282
CrossRef43
Matthew S. Rubino, Raafat Z. Abdel-Misih, Joseph J. Bennett, Nicholas J. Petrelli. (2011) Peritoneal surface malignancies and regional treatment: A review of the literature. Surgical Oncology
CrossRef44
Moon Ki Choi, Byung-Jin Ahn, Dong-Seok Yim, Young Suk Park, Sung Kim, Tae Sung Sohn, Jae Hyung Noh, Jin Seok Heo, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang. (2011) Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. Cancer Chemotherapy and Pharmacology 67:1, 5-11
CrossRef45
Akul Singhania, Sherry Y. Wu, Nigel A. J. McMillan. (2011) Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration. Journal of Drug Delivery 2011, 1-7
CrossRef46
Jean-Sebastien Frenel, Christophe Leux, Luc Pouplin, Gwenael Ferron, Dominique Berton-Rigaud, Emmanuelle Bourbouloux, François Dravet, Isabelle Jaffre, Jean-Marc Classe. (2011) Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. Journal of Surgical Oncology 103:1, 10-16
CrossRef47
Franco Roviello, Enrico Pinto, Giovanni Corso, Corrado Pedrazzani, Stefano Caruso, Marco Filippeschi, Roberto Petrioli, Stefania Marsili, Maria Antonietta Mazzei, Daniele Marrelli. (2010) Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. Journal of Surgical Oncology 102:6, 663-670
CrossRef48
Robert J. Morgan, Lucille Leong, Warren Chow, David Gandara, Paul Frankel, Agustin Garcia, Heinz-Josef Lenz, James H. Doroshow. (2010) Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Investigational New Drugs
CrossRef49
Walter H. Gotlieb. (2010) Intraperitoneal Chemotherapy. International Journal of Gynecological Cancer 20, S14-S16
CrossRef50
Sang-Wun Kim, Jiheum Paek, Eun-Ji Nam, Sung-Hoon Kim, Jae-Hoon Kim, Young-Tae Kim. (2010) The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 152:2, 195-199
CrossRef51
Ze Lu, Jie Wang, M Guillaume Wientjes, Jessie L-S Au. (2010) Intraperitoneal therapy for peritoneal cancer. Future Oncology 6:10, 1625-1641
CrossRef52
Howard M. Katzenstein, Sarah Petricca, Richard Ricketts, Karen Wasilewski-Masker, Christie Powell, Louis Rapkin, Bradley George, William G. Woods, Thomas A. Olson. (2010) Intracavitary cisplatin therapy for pediatric malignancies. Pediatric Blood & Cancer 55:3, 452-456
CrossRef53
Yasumichi Yagi, Sachio Fushida, Shinichi Harada, Tomoya Tsukada, Jun Kinoshita, Katsunobu Oyama, Hideto Fujita, Itasu Ninomiya, Takashi Fujimura, Masato Kayahara, Seigo Kinuya, Masakazu Yashiro, Kousei Hirakawa, Tetsuo Ohta. (2010) Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemotherapy and Pharmacology 66:4, 745-753
CrossRef54
Alok C. Pant, Antonio Santillan, Teresa Diaz-Montes, Robert L. Giuntoli, Robert E. Bristow. (2010) Splenectomy in Cytoreductive Surgery for Advanced Ovarian Cancer and Subsequent Intraperitoneal Chemotherapy. Journal of Gynecologic Surgery 26:3, 179-182
CrossRef55
TS Kristedja, RJ Morgan, M Cristea. (2010) Targeted agents in ovarian cancer. Women's Health 6:5, 679-694
CrossRef56
Otto Metzger-Filho, Camilo Moulin, Veronique DʼHondt. (2010) First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions. Current Opinion in Oncology 22:5, 513-520
CrossRef57
G. D. Aletti, D. Nordquist, L. Hartmann, M. Gallenberg, H. J. Long, W. A. Cliby. (2010) From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. Annals of Oncology 21:9, 1772-1778
CrossRef58
T Pencavel, R Seth, A Hayes, A Melcher, H Pandha, R Vile, K J Harrington. (2010) Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?. Gene Therapy 17:8, 949-960
CrossRef59
Scott D. Richard, Paniti Sukumvanich, Jamie L. Lesnock, William C. McBee, Sushil Beriwal, Robert P. Edwards, Kristin K. Zorn, Thomas C. Krivak. (2010) Intraperitoneal Catheter Leads to Prolongation of the Time to Normalization of Serum CA125 Levels. International Journal of Gynecological Cancer 20:6, 932-935
CrossRef60
C. Pomel, G. Ferron, G. Lorimier, A. Rey, C. Lhomme, J.M. Classe, J.M. Bereder, F. Quenet, P. Meeus, F. Marchal, P. Morice, D. Elias. (2010) Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. European Journal of Surgical Oncology (EJSO) 36:6, 589-593
CrossRef61
Antonio González-Martín, Gemma Toledo, Luis Chiva. (2010) Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting. Clinical and Translational Oncology 12:6, 418-430
CrossRef62
Valentina Guarneri, Federico Piacentini, Elena Barbieri, Pier Franco Conte. (2010) Achievements and unmet needs in the management of advanced ovarian cancer. Gynecologic Oncology 117:2, 152-158
CrossRef63
Joyce N. Barlin, Robert E. Bristow, Karen Bleich, Robert L. Giuntoli, Sharon Thompson, Teresa P. Diaz-Montes. (2010) Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced müllerian cancer: a pilot study. Clinical Imaging 34:3, 191-195
CrossRef64
Gaurav Bajaj, Yoon Yeo. (2010) Drug Delivery Systems for Intraperitoneal Therapy. Pharmaceutical Research 27:5, 735-738
CrossRef65
Liz Y Han, Emma Kipps, Stan B Kaye. (2010) Current treatment and clinical trials in ovarian cancer. Expert Opinion on Investigational Drugs 19:4, 521-534
CrossRef66
Heidi J. Gray, Chirag A. Shah, Ron E. Swensen, Hisham K. Tamimi, Barbara A. Goff. (2010) Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecologic Oncology 116:3, 340-344
CrossRef67
Oliver Zivanovic, Camelia S. Sima, Alexia Iasonos, William J. Hoskins, Pavani R. Pingle, Mario M.M. Leitao, Yukio Sonoda, Nadeem R. Abu-Rustum, Richard R. Barakat, Dennis S. Chi. (2010) The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecologic Oncology 116:3, 351-357
CrossRef68
Jamie L. Lesnock, Scott D. Richard, Kristin K. Zorn, Thomas C. Krivak, Sushil Beriwal, Paniti Sukumvanich, William C. McBee, Joseph L. Kelley, Robert P. Edwards. (2010) Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecologic Oncology 116:3, 345-350
CrossRef69
Wim P. Ceelen, Michael F. Flessner. (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nature Reviews Clinical Oncology 7:2, 108-115
CrossRef70
Anil K. Sood, Robert L. Coleman. (2010) Targeted therapy in gynecologic oncology: Biology, strategy, and assessment. Gynecologic Oncology 116:2, 155-156
CrossRef71
Marco Fraccalvieri, Paolo Simone, Francesco Bruno, Piero Gaglia, Franco Ribero, Stefano Scuderi, Raffaele Seghesio, Manuela Monni, Claudio Zanon. (2010) Ramirezʼs Abdominoplasty Technique Combined With Intraperitoneal Chemohyperthermia After Surgical Cytoreductive Procedures for the Treatment of Advanced Intraperitoneal Cancer in Patients With Ventral Hernia. Annals of Plastic Surgery 64:2, 187-192
CrossRef72
Anda M. Vlad, Raluca A. Budiu, Diana E. Lenzner, Yun Wang, Julia A. Thaller, Kelly Colonello, Peggy A. Crowley-Nowick, Joseph L. Kelley, Fredric V. Price, Robert P. Edwards. (2010) A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunology, Immunotherapy 59:2, 293-301
CrossRef73
Cyril William Helm, Scott D. Richard, Jianmin Pan, David Bartlett, Martin D. Goodman, Rick Hoefer, Sam S. Lentz, Edward A. Levine, Brian W. Loggie, Daniel S. Metzinger, Brigitte Miller, Lynn Parker, James E. Spellman, Paul H. Sugarbaker, Robert P. Edwards, Shesh N. Rai. (2010) Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. International Journal of Gynecological Cancer 20:1, 61-69
CrossRef74
William R. Robinson, Julie Beyer. (2010) Factors Affecting the Completion of Intraperitoneal Chemotherapy in Women With Ovarian Cancer. International Journal of Gynecological Cancer 20:1, 70-74
CrossRef75
Susana M. Campos, Sue Ghosh. (2010) A Current Review of Targeted Therapeutics for Ovarian Cancer. Journal of Oncology 2010, 1-11
CrossRef76
Claudia Marchetti, Carmela Pisano, Gaetano Facchini, Giovanni Salvatore Bruni, Francesca Paola Magazzino, Simona Losito, Sandro Pignata. (2010) First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Review of Anticancer Therapy 10:1, 47-60
CrossRef77
Wim P. Ceelen, Yves Nieuwenhove, Simon Belle, Hannelore Denys, Piet Pattyn. (2009) Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer. Annals of Surgical Oncology
CrossRef78
Michael A. Bookman. (2009) Trials With Impact on Clinical Management. International Journal of Gynecological Cancer 19:Suppl 2, S55-S62
CrossRef79
Jennifer Squires. (2009) Anal Fissures Associated With Targeted Therapies in Ovarian Cancer. Clinical Journal of Oncology Nursing 13:6, 638-642
CrossRef80
Francisco C. Muñoz-Casares, Sebastián Rufián, María J. Rubio, Carlos J. Díaz, Rafael Díaz, Ángela Casado, Álvaro Arjona, María C. Muñoz-Villanueva, Jordi Muntané. (2009) The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clinical and Translational Oncology 11:11, 753-759
CrossRef81
Thomas C. Krivak, Chunqiao Tian, G. Scott Rose, Deborah K. Armstrong, G. Larry Maxwell. (2009) A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172. Gynecologic Oncology 115:1, 81-85
CrossRef82
Bryan T Hennessy, Robert L Coleman, Maurie Markman. (2009) Ovarian cancer. The Lancet 374:9698, 1371-1382
CrossRef83
Terence C. Chua, Winston Liauw, Greg Robertson, David L. Morris. (2009) Establishing evidence for change in ovarian cancer surgery — Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecologic Oncology 115:1, 166-168
CrossRef84
Leigh G. Seamon, Matthew J. Carlson, Debra L. Richardson, David E. Cohn, Jeffrey M. Fowler, Larry J. Copeland, David M. O'Malley. (2009) Outpatient Platinum-Taxane Intraperitoneal Chemotherapy Regimen for Ovarian Cancer. International Journal of Gynecological Cancer 19:7, 1195-1198
CrossRef85
Aviram Nissan, Alexander Stojadinovic, Alfredo Garofalo, Jesus Esquivel, Pompiliu Piso. (2009) Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. Journal of Surgical Oncology 100:4, 335-344
CrossRef86
Joseph J. Ivy, Melissa Geller, Serena M. Pierson, Amy L. Jonson, Peter A. Argenta. (2009) Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: A single institution's experience. Gynecologic Oncology 114:3, 420-423
CrossRef87
Ming-Shien Yen, Nae-Fong Twu, Chiung-Ru Lai, Huann-Cheng Horng, Kuan-Chong Chao, Chi-Mou Juang. (2009) Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. Gynecologic Oncology 114:3, 415-419
CrossRef88
Yi-Yu Lin, Jia-Je Li, Chih-Hsien Chang, Yi-Ching Lu, Jeng-Jong Hwang, Yun-Long Tseng, Wuu-Jyh Lin, Gann Ting, Hsin-Ell Wang. (2009) Evaluation of Pharmacokinetics of 111 In-Labeled VNB-PEGylated Liposomes After Intraperitoneal and Intravenous Administration in a Tumor/Ascites Mouse Model. Cancer Biotherapy & Radiopharmaceuticals 24:4, 453-460
CrossRef89
Kellie S. Matthews, Ronald D. Alvarez, David T. Curiel. (2009) Advancements in adenoviral based virotherapy for ovarian cancer. Advanced Drug Delivery Reviews 61:10, 836-841
CrossRef90
Harriet O. Smith, James Moon, Sharon P. Wilczynski, Amy D. Tiersten, Edward V. Hannigan, William R. Robinson, Saul E. Rivkin, Garnet L. Anderson, P.Y. Liu, Maurie Markman. (2009) Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecologic Oncology 114:2, 206-209
CrossRef91
R. Wendel Naumann, Paniti Sukumvanich, Robert P. Edwards. (2009) Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. Gynecologic Oncology 114:1, 37-41
CrossRef92
Terence C. Chua, Winston Liauw, Greg Robertson, Whay-Kuang John Chia, Khee-Chee Soo, Abdulaziz AlObaid, Khaled Al-Mohaimeed, David L. Morris. (2009) Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecologic Oncology 114:1, 137-139
CrossRef93
Ritu Salani, Floor J Backes, Larry J Copeland. (2009) Overview of epithelial ovarian cancer and updates in management strategies. Expert Review of Obstetrics & Gynecology 4:4, 383-399
CrossRef94
Chunyan Lan, Yanfang Li, Jihong Liu. (2009) Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer. Gynecologic Oncology 114:1, 42-47
CrossRef95
Keiichi Fujiwara, Shoji Nagao, Junzo Kigawa, Jun Noma, Nobuo Akamatsu, Yasunari Miyagi, Fumitaka Numa, Makoto Okada, Eriko Aotani. (2009) Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer. International Journal of Gynecological Cancer 19:5, 834-837
CrossRef96
Alan D. Hutson, Maurie Markman, Mark F. Brady. (2009) A permutation test approach to phase II historical control trials. Journal of Applied Statistics 36:6, 589-599
CrossRef97
Stacey Su. (2009) Mesothelioma: Path to Multimodality Treatment. Seminars in Thoracic and Cardiovascular Surgery 21:2, 125-131
CrossRef98
Perry Shen, John H. Stewart, Edward A. Levine. (2009) Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Non-Colorectal Indications. Current Problems in Cancer 33:3, 168-193
CrossRef99
Siobhan M. Kehoe, Ned L. Williams, Rasheed Yakubu, Douglas A. Levine, Dennis S. Chi, Paul J. Sabbatini, Carol A. Aghajanian, Richard R. Barakat, Nadeem R. Abu-Rustum. (2009) Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. Gynecologic Oncology 113:2, 228-232
CrossRef100
Kurt Van der Speeten, Oswald A. Stuart, Paul H. Sugarbaker. (2009) Pharmacokinetics and Pharmacodynamics of Perioperative Cancer Chemotherapy in Peritoneal Surface Malignancy. The Cancer Journal 15:3, 216-224
CrossRef101
Kurt Speeten, O. A. Stuart, H. Mahteme, P. H. Sugarbaker. (2009) A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemotherapy and Pharmacology 63:5, 799-805
CrossRef102
AM Young, Iain A McNeish. (2009) Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. Future Oncology 5:3, 339-357
CrossRef103
Ernest S. Han, Paul Lin, Mark Wakabayashi. (2009) Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer. Current Treatment Options in Oncology 10:1-2, 54-66
CrossRef104
Maurie Markman. (2009) An Update on the Use of Intraperitoneal Chemotherapy in the Management of Ovarian Cancer. The Cancer Journal 15:2, 105-109
CrossRef105
Amy D. Tiersten, P.Y. Liu, Harriet O. Smith, Sharon P. Wilczynski, William R. Robinson, Maurie Markman, David S. Alberts. (2009) Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecologic Oncology 112:3, 444-449
CrossRef106
S Janczar, JS Graham, AJW Paige, H Gabra. (2009) Targeting locoregional peritoneal dissemination in ovarian cancer. Expert Review of Obstetrics & Gynecology 4:2, 133-147
CrossRef107
Sheray N. Chin, Victoria Pinto, Barry Rosen, Amit Oza, Jason Dodge, Joan Murphy, Helen Mackay. (2009) Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecologic Oncology 112:3, 450-454
CrossRef108
Joanne Morrison, Simon S. Briggs, Nicola K. Green, Clemens Thoma, Kerry D. Fisher, Sean Kehoe, Leonard W. Seymour. (2009) Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer. Human Gene Therapy 20:3, 239-251
CrossRef109
Paul H Sugarbaker. (2009) Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. Current Opinion in Obstetrics and Gynecology 21:1, 15-24
CrossRef110
Fiona Collinson, Gordon Jayson. (2009) New therapeutic agents in ovarian cancer. Current Opinion in Obstetrics and Gynecology 21:1, 44-53
CrossRef111
Maurie Markman, Mark Brady, Alan Hutson, Jonathan S. Berek. (2009) Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer. International Journal of Gynecological Cancer 19:2, 223-229
CrossRef112
Bernard Royer, Vincent Jullien, Emmanuel Guardiola, Bruno Heyd, Bruno Chauffert, Jean-Pierre Kantelip, Xavier Pivot. (2009) Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration. Clinical Pharmacokinetics 48:3, 169-180
CrossRef113
Jin Hwi Kim, Joon Mo Lee, Ki Sung Ryu, Yong Seok Lee, Yong Gyu Park, Soo Young Hur, Keun Ho Lee, Sung Ha Lee, Seung Jo Kim. (2009) Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. Journal of Surgical Oncologyn/a-n/a
CrossRef114
Antonio Barrasa, Kurt Van de Speeten, Oswald Anthony Stuart, Paul Hendrick Sugarbaker, Luiggi Zappa. (2009) Bases farmacológicas de la quimioterapia perioperatoria en la carcinomatosis peritoneal. Cirugía Española 85:1, 3-13
CrossRef115
S. MUGERWA, V. LEKHARAJU, C.F. KIIRE. (2009) Management of peritoneal carcinomatosis secondary to metastatic cancer of unknown primary in men. European Journal of Cancer Care 18:1, 22-27
CrossRef116
Antonio Barrasa, Kurt van de Speeten, Oswald Anthony Stuart, Paul Hendrick Sugarbaker, Luiggi Zappa. (2009) Rationale for perioperative chemotherapy treatment in peritoneal carcinomatosis. Cirugía Española (English Edition) 85:1, 3-13
CrossRef117
William P. Tew, Stuart M. Lichtman. (2008) Ovarian Cancer in Older Women. Seminars in Oncology 35:6, 582-589
CrossRef118
Rolf D. Issels. (2008) Hyperthermia adds to chemotherapy. European Journal of Cancer 44:17, 2546-2554
CrossRef119
S. NAGAO, K. FUJIWARA, R. OHISHI, Y. NAKANISHI, N. IWASA, M. SHIMIZU, T. GOTO, K. SHIMOYA. (2008) Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer. International Journal of Gynecological Cancer 18:6, 1210-1214
CrossRef120
George A. Omura. (2008) Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience. Seminars in Oncology 35:5, 507-521
CrossRef121
Maurie Markman. (2008) Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends in Pharmacological Sciences 29:10, 515-519
CrossRef122
Charles A. Coltman. (2008) The Southwest Oncology Group: Progress in Cancer Research. Seminars in Oncology 35:5, 545-552
CrossRef123
C. William Helm, Robert E. Bristow, Shigeki Kusamura, Dario Baratti, Marcello Deraco. (2008) Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. Journal of Surgical Oncology 98:4, 283-290
CrossRef124
Lana Bijelic, Tristan D. Yan, Paul H. Sugarbaker. (2008) Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. Journal of Surgical Oncology 98:4, 295-299
CrossRef125
W.R. ROBINSON, N. DAVIS, A.S. ROGERS. (2008) Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer. International Journal of Gynecological Cancer 18:5, 891-895
CrossRef126
A. GADDUCCI, P.F. CONTE. (2008) Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. International Journal of Gynecological Cancer 18:5, 943-953
CrossRef127
Toru Sugiyama, Ikuo Konishi. (2008) Emerging drugs for ovarian cancer. Expert Opinion on Emerging Drugs 13:3, 523-536
CrossRef128
Mohan K Tummala, Suganthi Alagarsamy, William P McGuire. (2008) Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?. Expert Review of Anticancer Therapy 8:7, 1135-1147
CrossRef129
Oliver Zivanovic, Richard R. Barakat, Paul J. Sabbatini, Carol L. Brown, Jason A. Konner, Carol A. Aghajanian, Nadeem R. Abu-Rustum, Douglas A. Levine. (2008) Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment. Cancer 112:12, 2690-2697
CrossRef130
Nick M. Spirtos. (2008) Intraperitoneal Chemotherapy: Practicality Versus Theory. Clinical Ovarian Cancer 1:1, 72-74
CrossRef131
Aarati Ranganathan, J. Tate Thigpen. (2008) Highlights from: The Annual Meeting of the Society of Gynecologic Oncologists; March 9–12, 2008; Tampa, FL. Clinical Ovarian Cancer 1:1, 10-14
CrossRef132
A. G. Zeimet, D. Reimer, N. Concin, S. Braun, C. Marth. (2008) Primary chemotherapy and maintenance therapy in epithelial ovarian cancer. memo - Magazine of European Medical Oncology 1:2, 99-102
CrossRef133
Robin L Jones, Vasilios Karavasilis, Stanley B Kaye. (2008) Paclitaxel in the management of ovarian cancer. Expert Review of Obstetrics & Gynecology 3:3, 287-299
CrossRef134
J D Wright, T Doan, R McBride, J S Jacobson, D L Hershman. (2008) Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. British Journal of Cancer 98:7, 1197-1203
CrossRef135
Eelco Bree, Hilde Rosing, Dimitris Filis, John Romanos, Maria Melisssourgaki, Markos Daskalakis, Maria Pilatou, Elias Sanidas, Panagiotis Taflampas, Konstantinos Kalbakis, Jos H. Beijnen, Dimitris D. Tsiftsis. (2008) Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study. Annals of Surgical Oncology 15:4, 1183-1192
CrossRef136
Richard E. Royal, James F. Pingpank. (2008) Diagnosis and Management of Peritoneal Carcinomatosis Arising From Adenocarcinoma of the Colon and Rectum. Seminars in Oncology 35:2, 183-191
CrossRef137
Maurie Markman. (2008) Evidence-based chemotherapy administration in advanced ovarian cancer: An impressive past, a disquieting present and an uncertain future. Gynecologic Oncology 109:1, 4-7
CrossRef138
M.T. Seymour, I. Trigonis, P.J. Finan, F. Halstead, R. Dunham, G. Wilson, D. Farrugia, J.D. Chester, J. King, C.B. Brown, M.L. Slevin, S.P. Joel. (2008) A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. European Journal of Surgical Oncology (EJSO) 34:4, 403-409
CrossRef139
Destin Black, Douglas A. Levine, Linda Nicoll, Joanne F. Chou, Alexia Iasonos, Carol L. Brown, Yukio Sonoda, Dennis S. Chi, Mario M. Leitao, Nadeem R. Abu-Rustum, Sarah E. Ferguson, Richard R. Barakat. (2008) Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecologic Oncology 109:1, 39-42
CrossRef140
M. MARKMAN. (2008) What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?. International Journal of Gynecological Cancer 18, 36-39
CrossRef141
M. MARKMAN. (2008) Strategies to examine new compounds for intraperitoneal use in ovarian cancer. International Journal of Gynecological Cancer 18, 33-35
CrossRef142
Maurie Markman. (2008) Critical thinking: An essential role in both the conduct and interpretation of gynecologic cancer clinical research. Gynecologic Oncology 108:3, 462-465
CrossRef143
E.L. TRIMBLE, M.C. CHRISTIAN. (2008) National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. International Journal of Gynecological Cancer 18, 26-28
CrossRef144
Bernard Royer, Delphine Delroeux, Emmanuel Guardiola, Marielle Combe, Guillaume Hoizey, Damien Montange, Jean-Pierre Kantelip, Bruno Chauffert, Bruno Heyd, Xavier Pivot. (2008) Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemotherapy and Pharmacology 61:3, 415-421
CrossRef145
R Fruscio, N Colombo, A A Lissoni, A Garbi, R Fossati, N Ieda', V Torri, C Mangioni. (2008) A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. British Journal of Cancer 98:4, 720-727
CrossRef146
Lisa M. Landrum, Michael A. Gold, Kathleen N. Moore, Tashanna K.N. Myers, D.S. McMeekin, Joan L. Walker. (2008) Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates. Gynecologic Oncology 108:2, 342-347
CrossRef147
Joanne Morrison, Simon S Briggs, Nicola Green, Kerry Fisher, Vladimir Subr, Karel Ulbrich, Sean Kehoe, Leonard W Seymour. (2008) Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor. Molecular Therapy 16:2, 244-251
CrossRef148
Oliver Zivanovic, Eric L. Eisenhauer, Qin Zhou, Alexia Iasonos, Paul Sabbatini, Yukio Sonoda, Nadeem R. Abu-Rustum, Richard R. Barakat, Dennis S. Chi. (2008) The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic Oncology 108:2, 287-292
CrossRef149
Carolyn D. Runowicz. (2008) Intraperitoneal Chemotherapy in Ovarian Cancer: An Update. The Cancer Journal 14:1, 7-9
CrossRef150
Thomas Lowe, Betty Ferrell, Lucille Leong. (2007) Quality-of-Life Issues in the Management of Epithelial Ovarian Cancer. Current Treatment Options in Oncology 8:6, 402-416
CrossRef151
John J. Kavanagh. (2007) Intraperitoneal chemotherapy in the treatment of ovarian cancer. Journal of Surgical Oncology 96:7, 541-542
CrossRef152
Karin Sorenmo, Marissa Samluk, Craig Clifford, Jennifer Baez, Jeffrey S. Barrett, Robert Poppenga, Beth Overley, Katherine Skorupski, Karen Oberthaler, Tom Van Winkle, Gabriela Seller, Frances Shofer. (2007) Clinical and Pharmacokinetic Characteristics of Intracavitary Administration of Pegylated Liposomal Encapsulated Doxorubicin in Dogs with Splenic Hemangiosarcoma. Journal of Veterinary Internal Medicine 21:6, 1347-1354
CrossRef153
F. C. Muñoz-Casares, S. Rufián, M. J. Rubio, E. Lizárraga, C. Díaz-Iglesias, E. Aranda, R. Ciria, J. Muntané, P. Barrios, J. Torres-Melero, S. González-Moreno, L. González-Bayón, B. Camps, P. Bretcha, J. Farré, G. Ortega-Pérez, A. Gómez-Portilla. (2007) Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clinical and Translational Oncology 9:10, 652-662
CrossRef154
S Nasim Ali, Jonathan A Ledermann. (2007) Current practice and new developments in ovarian cancer chemotherapy. The Obstetrician & Gynaecologist 9:4, 265-269
CrossRef155
L. NIEVES, J. CURRIE, J. HOFFMAN, J.I. SOROSKY. (2007) Ototoxicity after intraperitoneal chemotherapy: a case report. International Journal of Gynecological Cancer 17:5, 1133-1135
CrossRef156
M. PENDERGRASS, M.E. GORDINIER, L.P. PARKER, D.S. METZINGER, C.W. HELM. (2007) Retraction of an intraperitoneal chemotherapy port: a case report and literature review. International Journal of Gynecological Cancer 17:5, 1131-1133
CrossRef157
T. Petit. (2007) Cancers gynécologiques. Oncologie 9:7-8, 517-520
CrossRef158
Eric L. Eisenhauer, William P. Tew, Douglas A. Levine, Stuart M. Lichtman, Carol L. Brown, Carol Aghajanian, Jae Huh, Richard R. Barakat, Dennis S. Chi. (2007) Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy. Gynecologic Oncology 106:2, 381-387
CrossRef159
Max Tsai, Ze Lu, Jie Wang, Teng-Kuang Yeh, M. Guillaume Wientjes, Jessie L.-S. Au. (2007) Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel. Pharmaceutical Research 24:9, 1691-1701
CrossRef160
Angèle L.M. Oei, Leon F.A.G. Massuger, Wim J.G. Oyen. (2007) Extraperitoneal Leakage as a Possible Explanation for Failure of One-Time Intraperitoneal Treatment in Ovarian Cancer. Cancer Biotherapy & Radiopharmaceuticals 22:4, 508-514
CrossRef161
Jeong Hoon Bae, Joon Mo Lee, Ki Sung Ryu, Yong Seok Lee, Yong Gyu Park, Soo Young Hur, Woong Shik Ahn, Seong Eun Namkoong. (2007) Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecologic Oncology 106:1, 193-200
CrossRef162
Samuel S. Lentz, Brigitte E. Miller, Gregory L. Kucera, Edward A. Levine. (2007) Intraperitoneal hyperthermic chemotherapy using carboplatin: A phase I analysis in ovarian carcinoma. Gynecologic Oncology 106:1, 207-210
CrossRef163
Thomas Lowe, Robert J Morgan. (2007) Intraperitoneal chemotherapy of ovarian cancer. Women's Health 3:4, 433-440
CrossRef164
A. Poveda, R. Salazar, J. M. Campo, C. Mendiola, J. Cassinello, B. Ojeda, J. A. Arranz, A. Oaknin, J. García-Foncillas, M. J. Rubio, A. González Martín. (2007) Update in the management of ovarian and cervical carcinoma. Clinical and Translational Oncology 9:7, 443-451
CrossRef165
A. González Martín. (2007) Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: A new standard in patient care?. Clinical and Translational Oncology 9:7, 409-411
CrossRef166
Angèle L. Oei, René H. Verheijen, Michael V. Seiden, Benedict B. Benigno, Alberto Lopes, John T. Soper, Agamemnon A. Epenetos, Leon F. Massuger. (2007) Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. International Journal of Cancer 120:12, 2710-2714
CrossRef167
M. Fung-Kee-Fung, D. Provencher, B. Rosen, P. Hoskins, L. Rambout, T. Oliver, W. Gotlieb, A. Covens. (2007) Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care. Gynecologic Oncology 105:3, 747-756
CrossRef168
Maurie Markman. (2007) A relevant historical perspective on the current toxicity of IP chemotherapy: Implications for the future. Gynecologic Oncology 105:3, 561-562
CrossRef169
Giovanni D. Aletti, Mary M. Gallenberg, William A. Cliby, Aminah Jatoi, Lynn C. Hartmann. (2007) Current Management Strategies for Ovarian Cancer. Mayo Clinic Proceedings 82:6, 751-770
CrossRef170
G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, L. C. Hartmann. (2007) Current Management Strategies for Ovarian Cancer. Mayo Clinic Proceedings 82:6, 751-770
CrossRef171
E.L. TRIMBLE, J. DAVIS, P. DISAIA, K. FUJIWARA, D. GAFFNEY, G. KRISTENSEN, J. LEDERMANN, J. PFISTERER, M. QUINN, N. REED, M. SCHOENFELDT, J.T. THIGPEN, . (2007) Clinical trials in gynecological cancer. International Journal of Gynecological Cancer 17:3, 547-556
CrossRef172
Patrick Petignat, Andreas du Bois, Ilan Bruchim, Daniel Fink, Diane M. Provencher. (2007) Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?. Critical Reviews in Oncology/Hematology 62:2, 137-147
CrossRef173
Pierre-Emmanuel Colombo, Mahfoud Boustta, Sylvain Poujol, Frédéric Pinguet, Philippe Rouanet, Françoise Bressolle, Michel Vert. (2007) Biodistribution of doxorubicin-alkylated poly(l-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. European Journal of Pharmaceutical Sciences 31:1, 43-52
CrossRef174
A. Poveda Velasco, A. Casado Herráez, A. Cervantes Ruipérez, D. Gallardo Rincón, E. García García, A. González Martín, G. López García, C. Mendiola Fernández, B. Ojeda González. (2007) Treatment guidelines in ovarian cancer. Clinical and Translational Oncology 9:5, 308-316
CrossRef175
L.M. HESS, M. BENHAM-HUTCHINS, T.J. HERZOG, C.-H. HSU, D.C. MALONE, G.H. SKREPNEK, M.K. SLACK, D.S. ALBERTS. (2007) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. International Journal of Gynecological Cancer 17:3, 561-570
CrossRef176
Christian Marth, Joan L. Walker, Richard R. Barakat, Antonio Casado, Angiolo Gadducci, Brigitte Miller, Franco Odicino, Eric Pujade-Lauraine, Jalid Sehouli, Claes Tropé, Lari Wenzel, Alain G. Zeimet. (2007) Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 109:4, 645-649
CrossRef177
Laurie Elit, Thomas K. Oliver, Allan Covens, Janice Kwon, Michael Fung-Kee Fung, Holger W. Hirte, Amit M. Oza, . (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. Cancer 109:4, 692-702
CrossRef178
Anne OʼMeara Rodriguez. (2007) Ambivalency at the bedside: intraperitoneal chemotherapy. Current Opinion in Obstetrics and Gynecology 19:1, 1-2
CrossRef179
Ignace Vergote, Toon Van Gorp, Isabelle Cadron, Karin Leunen, Patrick Neven, Frederic Amant. (2007) Improving outcome in the first-line management of advanced ovarian cancer. European Journal of Cancer Supplements 5:1, 23-28
CrossRef180
Paul A. DiSilvestro, Margaret Fisher, Michael L. Pearl, Ann Buhl, Eva Chalas, Fidel A. Valea. (2007) Pilot Phase 2 Trial of 4 Months of Maintenance Pegylated Liposomal Doxorubicin in Patients with Advanced Ovarian Cancer after Complete Response to Platinum and Paclitaxel-Based Chemotherapy. Gynecologic and Obstetric Investigation 63:1, 1-6
CrossRef181
K. FUJIWARA, D. ARMSTRONG, M. MORGAN, M. MARKMAN. (2007) Principles and practice of intraperitoneal chemotherapy for ovarian cancer. International Journal of Gynecological Cancer 17:1, 1-20
CrossRef182
Teruo ITOH, Kazuyuki UCHIDA, Atsuko KOJIMOTO, Ayako IKEDA, Kazumi NIBE, Hiroki SHII. (2007) Metastatic Ovarian Adenocarcinoma in a Dog Treated with Ovariohysterectomy and Intracavitary Chemotherapy. Japanese Journal of Veterinary Anesthesia & Surgery 38:3/4, 63-68
CrossRef183
C.W. HELM, C.R. TOLER, R.S. MARTIN, M.E. GORDINIER, L.P. PARKER, D.S. METZINGER, R.P. EDWARDS. (2007) Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity. International Journal of Gynecological Cancer 17:1, 204-209
CrossRef184
David S. Alberts. (2006) Introduction. Seminars in Oncology 33, 1-2
CrossRef185
Maurie Markman. (2006) Clinical Efficacy Supporting the Role of Intraperitoneal Drug Delivery in the Primary Chemotherapeutic Management of Small-Volume Residual Advanced Ovarian Cancer. Seminars in Oncology 33, 3-7
CrossRef186
Rodney P. Rocconi, Michael T. Numnum, Zeng B. Zhu, Baogen Lu, Minghui Wang, Angel A. Rivera, Mariam Stoff-Khalili, Ronald D. Alvarez, David T. Curiel, Sharmila Makhija. (2006) Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy. Gynecologic Oncology 103:3, 985-989
CrossRef187
Robert L. Coleman, Anil K. Sood. (2006) Historical progress in the initial management of ovarian cancer: Intraperitoneal chemotherapy. Current Oncology Reports 8:6, 455-464
CrossRef188
Robert L. Coleman. (2006) Intraperitoneal chemotherapy for frontline ovarian cancer therapy: Vindicated or vilified?. Current Oncology Reports 8:6, 439-440
CrossRef189
David S. Alberts, Ardie Delforge. (2006) Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life. Seminars in Oncology 33, 8-17
CrossRef190
Franco M. Muggia. (2006) New and Emerging Intraperitoneal (IP) Drugs for Ovarian Cancer Treatment. Seminars in Oncology 33, 18-24
CrossRef191
Sergio Pecorelli, Roberto Angioli, Brunella Pasinetti, Giancarlo Tisi, Franco Odicino. (2006) Systemic therapy for gynecological neoplasms: Ovary, cervix and endometrium. Update on Cancer Therapeutics 1:4, 515-538
CrossRef192
D.S. Alberts, M. Markman, F. Muggia, R.F. Ozols, E. Eldermire, M.A. Bookman, T. Chen, J. Curtin, L.M. Hess, L. Liebes, R.C. Young, E. Trimble. (2006) Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecologic Oncology 103:3, 783-792
CrossRef193
Eric L. Eisenhauer, Nadeem R. Abu-Rustum, Yukio Sonoda, Douglas A. Levine, Elizabeth A. Poynor, Carol Aghajanian, William R. Jarnagin, Ronald P. DeMatteo, Michael I. D'Angelica, Richard R. Barakat, Dennis S. Chi. (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecologic Oncology 103:3, 1083-1090
CrossRef194
C??cile Molucon-Chabrot, Nicolas Isambert, Laurent Benoit, Sylvie Zanetta, Jean Fraisse, Jean-Claude Guilland, Bernard Royer, Pascale Monin-Baroille, Michel Flesch, Pierre Fargeot, Bruno Coudert, Fran??oise Mayer, Pierre Fumoleau, Bruno Chauffert. (2006) Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anti-Cancer Drugs 17:10, 1211-1217
CrossRef195
Franco Muggia. (2006) More on intraperitoneal therapy. Gynecologic Oncology 103:2, 763
CrossRef196
Thomas J Herzog, Bhavana Pothuri. (2006) Ovarian cancer: a focus on management of recurrent disease. Nature Clinical Practice Oncology 3:11, 604-611
CrossRef197
R. Agarwal, M. Linch, S.B. Kaye. (2006) Novel therapeutic agents in ovarian cancer. European Journal of Surgical Oncology (EJSO) 32:8, 875-886
CrossRef198
Robert F. Ozols, Michael A. Bookman, Andreas du Bois, Jacobus Pfisterer, Alexander Reuss, Robert C. Young. (2006) Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. Gynecologic Oncology 103:1, 1-6
CrossRef199
N Frickhofen, W E Berdel, F Opri, R Haas, A Schneeweiss, M Sandherr, W Kuhn, D K Hossfeld, C Thomssen, H Heimpel, R Kreienberg, A Hinke, V Möbus. (2006) Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. Bone Marrow Transplantation 38:7, 493-499
CrossRef200
Eelco de Bree, Panayiotis A. Theodoropoulos, Hilde Rosing, John Michalakis, John Romanos, Jos H. Beijnen, Dimitris D. Tsiftsis. (2006) Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside. Cancer Treatment Reviews 32:6, 471-482
CrossRef201
Scott M. Eisenkop, Nick M. Spirtos, Wei-Chien Michael Lin. (2006) “Optimal” cytoreduction for advanced epithelial ovarian cancer: A commentary. Gynecologic Oncology 103:1, 329-335
CrossRef202
Sebastián Rufián, Francisco C. Muñoz-Casares, Javier Briceño, Carlos J. Díaz, María J. Rubio, Rosa Ortega, Rubén Ciria, Manuel Morillo, Enrique Aranda, Jordi Muntané, Carlos Pera. (2006) Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. Journal of Surgical Oncology 94:4, 316-324
CrossRef203
M. ALHAYKI, L. HOPKINS, T. LE, M. FUNG KEE FUNG. (2006) Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: a Canadian perspective. International Journal of Gynecological Cancer 16:5, 1761-1765
CrossRef204
Chad A Hamilton, Jonathan S Berek. (2006) Intraperitoneal chemotherapy for ovarian cancer. Current Opinion in Oncology 18:5, 507-515
CrossRef205
A. DU BOIS, B. SCHMALFELDT, W. MEIER, J. SEHOULI, J. PFISTERER. (2006) Ovarian cancer-can intraperitoneal therapy be regarded as new standard in Germany?. International Journal of Gynecological Cancer 16:5, 1756-1760
CrossRef206
Santiago González-Moreno. (2006) Surgical management of peritoneal carcinomatosis: from clinical research to standard of care. Clinical and Translational Oncology 8:8, 545-546
CrossRef207
Rodney P. Rocconi, Ashley S. Case, J. Michael Straughn, Jacob M. Estes, Edward E. Partridge. (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer. Cancer 107:3, 536-543
CrossRef208
Carolyn Runowicz. (2006) Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?. Nature Clinical Practice Oncology 3:8, 416-417
CrossRef209
E. de Bree, H. Rosing, J. Michalakis, J. Romanos, K. Relakis, P.A. Theodoropoulos, J.H. Beijnen, V. Georgoulias, D.D. Tsiftsis. (2006) Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. European Journal of Surgical Oncology (EJSO) 32:6, 666-670
CrossRef210
Maryam AlHayki, Laura Hopkins, Tien Le. (2006) Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer. Obstetrical & Gynecological Survey 61:8, 529-534
CrossRef211
Wayne A. McCreath, Eric L. Eisenhauer, Nadeem R. Abu-Rustum, Ennapadam S. Venkatraman, Aileen Caceres, Rachel Bier, Jae Huh, Jae Cho, Richard R. Barakat, Dennis S. Chi. (2006) Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. Gynecologic Oncology 102:1, 8-14
CrossRef212
Joan L. Walker. (2006) Intraperitoneal chemotherapy in patients with nodal metastasis. Gynecologic Oncology 102:1, 130
CrossRef213
Snehal Bhoola, William J. Hoskins. (2006) Diagnosis and Management of Epithelial Ovarian Cancer. Obstetrics & Gynecology 107:6, 1399-1410
CrossRef214
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Peters, Christine C., Krasner, Carolyn N., Roche, Maria, Horowitz, Neil S., Supko, Jeffrey G., Lee, Susanna I., Oliva, Esther, . (2006) Case 11-2006. New England Journal of Medicine 354:15, 1615-1625
Full Text215
Maurie Markman. (2006) Unresolved Issues in the Chemotherapeutic Management of Gynecologic Malignancies. Seminars in Oncology 33, 33-38
CrossRef216
A. Bois, B. Schmalfeldt, W. Meier, J. Sehouli, J. Pfisterer, die AGO Studiengruppe Ovarialkarzin (NOGGO). (2006) Ovarialkarzinom. Der Gynäkologe 39:4, 327-331
CrossRef217
Robert F. Ozols. (2006) Systemic Therapy for Ovarian Cancer: Current Status and New Treatments. Seminars in Oncology 33, 3-11
CrossRef218
Scott M. Eisenkop, Nick M. Spirtos, Wei-Chien Michael Lin. (2006) Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecologic Oncology 100:2, 344-348
CrossRef219
Ken Jaaback, Nick Johnson, Ken Jaaback. 2006. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. .
CrossRef220
Armstrong, Deborah K., Bundy, Brian, Wenzel, Lari, Huang, Helen Q., Baergen, Rebecca, Lele, Shashikant, Copeland, Larry J., Walker, Joan L., Burger, Robert A., . (2006) Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. New England Journal of Medicine 354:1, 34-43
Full Text221
Cannistra, Stephen A., . (2006) Intraperitoneal Chemotherapy Comes of Age. New England Journal of Medicine 354:1, 77-79
Full Text222
Edward L. Trimble, Michaele C. Christian. (2006) Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecologic Oncology 100:1, 3-4
CrossRef223
A. Astier. (2006) Formes galéniques nouvelles en cancérologie. Annales Pharmaceutiques Françaises 64:1, 23-35
CrossRef224
Joan L. Walker, Deborah K. Armstrong, Helen Q. Huang, Jeffrey Fowler, Kenneth Webster, Robert A. Burger, Daniel Clarke-Pearson. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 100:1, 27-32
CrossRef225
David S. Alberts, Edward V. Hannigan, Ping-Yu Liu, Caroline Jiang, Sharon Wilczynski, Larry Copeland, Maurie Markman. (2006) Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecologic Oncology 100:1, 133-138
CrossRef226
Tanya Dorff, Agustin Garcia. (2005) Intraperitoneal chemotherapy for the treatment of ovarian cancer. The Women's Oncology Review 5:4, 203-211
CrossRef227
Santiago González-Moreno. (2005) Cirugía citorreductora y quimioterapia intraperitoneal perioperatoria para las neoplasias con diseminación peritoneal: ha llegado el momento. Cirugía Española 78:6, 341-343
CrossRef228
A. POVEDA. (2005) Ovarian cancer: is the news good enough?. International Journal of Gynecological Cancer 15:s3, 298-306
CrossRef229
M.A. BOOKMAN. (2005) Standard treatment in advanced ovarian cancer in 2005: the state of the art. International Journal of Gynecological Cancer 15:s3, 212-220
CrossRef230
Bernard Royer, Emmanuel Guardiola, Emmanuel Polycarpe, Guillaume Hoizey, Delphine Delroeux, Marielle Combe, Lo??c Chaigneau, Emmanuel Samain, Bruno Chauffert, Bruno Heyd, Jean-Pierre Kantelip, Xavier Pivot. (2005) Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anti-Cancer Drugs 16:9, 1009-1016
CrossRef231
Franco Muggia, Rebecca Kosloff. (2005) Investigational agents for epithelial ovarian cancer. Expert Review of Anticancer Therapy 5:5, 855-868
CrossRef232
Evelyn D. Lobo, Joseph P. Balthasar. (2005) Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. Journal of Pharmaceutical Sciences 94:9, 1957-1964
CrossRef233
Mark J McKeage. (2005) New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opinion on Investigational Drugs 14:8, 1033-1046
CrossRef234
Angiolo Gadducci, Stefania Cosio, Pier Franco Conte, Andrea Riccardo Genazzani. (2005) Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. Critical Reviews in Oncology/Hematology 55:2, 153-166
CrossRef235
C Bengala, V Guarneri, J Ledermann, G Rosti, H Wandt, J-P Lotz, J H Cure, C Orlandini, P Ferrante, P F Conte, T Demirer. (2005) High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation 36:1, 25-31
CrossRef236
Wen-Shiung Liou, Nelson N.H. Teng, John K. Chan. (2005) A modified technique for insertion of intraperitoneal port for chemotherapy. Journal of Surgical Oncology 90:4, 247-248
CrossRef237
Sameer Sharma, Kunle Odunsi. (2005) Targeted therapy for epithelial ovarian cancer. Expert Opinion on Therapeutic Targets 9:3, 501-513
CrossRef238
Anil K Sood, Robert L Coleman, Judith K Wolf, David M Gershenson. (2005) Selected highlights from the 5th International Conference on Ovarian Cancer. Expert Opinion on Pharmacotherapy 6:7, 1269-1275
CrossRef239
Paul A Vasey. (2005) Intraperitoneal chemotherapy for epithelial ovarian carcinoma. Future Oncology 1:3, 289-292
CrossRef240
Scott M. Eisenkop, Nick M. Spirtos. (2005) Division of pedicles by stapling during cytoreductive surgery for ovarian cancer. Gynecologic Oncology 97:3, 852-857
CrossRef241
Paul H. Sugarbaker. (2005) Commentary. Journal of Surgical Oncology 90:2, 56-58
CrossRef242
A. du Bois, J Pfisterer. (2005) Future options for first-line therapy of advanced ovarian cancer. International Journal of Gynecological Cancer 15:s1, 42-50
CrossRef243
Trevor W. Reichman, Bernadette Cracchiolo, Jahir Sama, Margarette Bryan, Jonathan Harrison, Lillian Pliner, Lawrence E. Harrison. (2005) Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. Journal of Surgical Oncology 90:2, 51-56
CrossRef244
Lloyd R Kelland. (2005) Emerging drugs for ovarian cancer. Expert Opinion on Emerging Drugs 10:2, 413-424
CrossRef245
K. Fujiwara, S. Suzuki, H. Ishikawa, T. Oda, E. Aotani, I. Kohno. (2005) Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. International Journal of Gynecological Cancer 15:3, 426-431
CrossRef246
Keiichi Fujiwara, Maurie Markman, Mark Morgan, Robert L. Coleman. (2005) Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecologic Oncology 97:1, 10-15
CrossRef247
J. Gori, R. CastanO, M. Toziano, D. Habich, J. Staringer, D.G.B. De Quiros, N. Felci. (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer. International Journal of Gynecological Cancer 15:2, 233-239
CrossRef248
Sean Kehoe, Jo Morrison. (2005) Current management of ovarian carcinoma. Therapy 2:2, 275-286
CrossRef249
Christophe Tournigand. (2005) Intraperitoneal chemotherapy in ovarian cancer: who and when?. Current Opinion in Obstetrics and Gynecology 17:1, 83???86
CrossRef250
Jin Chen, Joseph P. Balthasar. (2005) High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. Journal of Chromatography B 816:1-2, 183-192
CrossRef251
Lainie Martin, Russell J Schilder. (2005) Front-Line Treatment of Epithelial Ovarian Cancer. American Journal of Cancer 4:4, 221-231
CrossRef252
Nicholas S Reed, Azmat H Sadozye. (2005) Role of chemotherapy in the management of epithelial ovarian cancer. Expert Review of Anticancer Therapy 5:1, 139-147
CrossRef253
Cannistra, Stephen A., . (2004) Cancer of the Ovary. New England Journal of Medicine 351:24, 2519-2529
Full Text254
Franco M. Muggia. (2004) Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. Seminars in Oncology 31, 19-24
CrossRef255
Antonio J González-Martín. (2004) Medical treatment of epithelial ovarian cancer. Expert Review of Anticancer Therapy 4:6, 1125-1143
CrossRef256
Franco Orsi, Paolo Della Vigna, Silvia Penco, Guido Bonomo, Elena Lovati, Massimo Bellomi. (2004) Percutaneous placement of peritoneal port-catheter in oncologic patients. European Radiology 14:11, 2020-2024
CrossRef257
D. Scott McMeekin, Todd Tillmanns, Taimur Chaudry, Michael Gold, Gary Johnson, Joan Walker, Robert Mannel. (2004) Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecologic Oncology 95:1, 157-164
CrossRef258
Claudio Zanon, Renzo Clara, Isabella Chiappino, Massimiliano Bortolini, Silvia Cornaglia, Paolo Simone, Francesco Bruno, Leonarda Riu, Mario Airoldi, Fulvia Pedani. (2004) Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer. World Journal of Surgery 28:10, 1040-1045
CrossRef259
M. S. Mano, A. Awada, A. Minisini, G. Atalay, L. D. Lago, F. Cardoso, M. Piccart. (2004) Remaining controversies in the upfront management of advanced ovarian cancer. International Journal of Gynecological Cancer 14:5, 707-720
CrossRef260
Bohuslav Melichar, Hana Urminská, Tereza Kohlová, Markéta Nová, Tomáš Česák. (2004) Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecologic Oncology 94:2, 267-276
CrossRef261
Scott M Eisenkop. (2004) Commenting on “Future directions in the surgical management of ovarian cancer” by Berman 90:s35–39. Gynecologic Oncology 94:1, 235-236
CrossRef262
Patrick J Stiff, Elizabeth J Shpall, P.Y Liu, Sharon P Wilczynski, Natalie S Callander, Sidney A Scudder, Abdul-Rahman Jazieh, Wolfram Samlowski, Jason McCoy, David S Alberts. (2004) Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecologic Oncology 94:1, 98-106
CrossRef263
C Pablo Carmignani, Paul H Sugarbaker. (2004) Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience. Expert Review of Anticancer Therapy 4:3, 477-487
CrossRef264
D. S. Alberts, C. Jiang, P. Y. Liu, S. Wilczynski, M. Markman, M. L. Rothenberg. (2004) Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. International Journal of Gynecological Cancer 14:2, 224-228
CrossRef265
Jean-Pascal Machiels, Filomena Mazzeo, Martine Berliere. (2004) Neoadjuvant chemotherapy versus primary surgery for advanced-stage ovarian cancer: the question remains opened. Gynecologic Oncology 92:3, 1018-1019
CrossRef266
Scott M. Eisenkop. (2004) LTE—commenting on “Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer” (90: 163–9). Gynecologic Oncology 92:3, 1017-1018
CrossRef267
P A Vasey. (2003) Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. British Journal of Cancer 89, S23-S28
CrossRef268
Lois A. Almadrones. (2003) Treatment Advances in Ovarian Cancer. Cancer Nursing 26:Supplement 6S, 16S???20S
CrossRef269
Maurie Markman. (2003) Toxicities of the platinum antineoplastic agents. Expert Opinion on Drug Safety 2:6, 597-607
CrossRef270
M. J. Piccart, A. Floquet, G. Scarfone, P. H. B. Willemse, J. Emerich, I. Vergote, L. Giurgea, C. Coens, A. Awada, J. B. Vermorken. (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. International Journal of Gynecological Cancer 13:s2, 196-203
CrossRef271
Christophe Tournigand, Christophe Louvet, Jean-Luc Molitor, Xavier Fritel, Nidal Dehni, Alain Sezeur, Alain Pigné, Jean Cady, Jacques Milliez, Aimery de Gramont. (2003) Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecologic Oncology 91:2, 341-345
CrossRef272
Gregory Friberg, Gini Fleming. (2003) Intraperitoneal chemotherapy for ovarian cancer. Current Oncology Reports 5:6, 447-453
CrossRef273
Maurie Markman, Paul Elson, Barb Kulp, Gertrude Peterson, Kristine Zanotti, Kenneth Webster, Jerome Belinson. (2003) Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia. Gynecologic Oncology 91:1, 118-122
CrossRef274
Keiichi Fujiwara, Noriaki Sakuragi, Sachiko Suzuki, Nobutaka Yoshida, Kenichiro Maehata, Masashi Nishiya, Takayuki Koshida, Hideaki Sawai, Eriko Aotani, Ichiro Kohno. (2003) First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecologic Oncology 90:3, 637-643
CrossRef275
Gavin C.E Stuart. (2003) First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecologic Oncology 90:3, S8-S15
CrossRef276
James L. Mulshine, Fred R. Hirsch. (2003) Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer 41, 163-174
CrossRef277
Evelyn D. Lobo, Joseph P. Balthasar. (2003) Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. Journal of Pharmaceutical Sciences 92:8, 1654-1664
CrossRef278
Pax H.B. Willemse, Elisabeth G.E. de Vries. (2003) Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?. Drug Resistance Updates 6:4, 165-167
CrossRef279
Scott M Eisenkop, Nick M Spirtos, Richard L Friedman, Wei-Chien Michael Lin, Albert L Pisani, Sergio Perticucci. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology 90:2, 390-396
CrossRef280
M.Janice Lu, Joan Sorich, Maitreyee Hazarika, Mimi Kim, Giuseppe Del Priore, Allan J Jacobs, Chang Chiang, Paul C Liu, Eileen Fusco, John P Curtin, Franco M Muggia. (2003) Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. Hematology/Oncology Clinics of North America 17:4, 969-975
CrossRef281
Maurie Markman. (2003) Optimizing primary chemotherapy in ovarian cancer. Hematology/Oncology Clinics of North America 17:4, 957-968
CrossRef282
Roshan Agarwal, Stan B. Kaye. (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Reviews Cancer 3:7, 502-516
CrossRef283
Alain G Zeimet, Christian Marth. (2003) Why did p53 gene therapy fail in ovarian cancer?. The Lancet Oncology 4:7, 415-422
CrossRef284
Faheez Mohamed, O.Anthony Stuart, Paul H Sugarbaker. (2003) Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions. Journal of Surgical Research 113:1, 114-120
CrossRef285
Maurie Markman. (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. The Lancet Oncology 4:5, 277-283
CrossRef286
F Mohamed, P Marchettini, O.A Stuart, D Yoo, P.H Sugarbaker. (2003) A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. European Journal of Surgical Oncology (EJSO) 29:3, 261-265
CrossRef287
K.B Hosie, D.J Kerr, J.A Gilbert, M Downes, G Lakin, G Pemberton, K Timms, A Young, A Stanley. (2003) A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel carrier solution. European Journal of Surgical Oncology (EJSO) 29:3, 254-260
CrossRef288
Susan E Conroy, Laura Baines, Kathleen Rodgers, Figen Deviren, Shelagh J Verco. (2003) Prevention of chemotherapy-induced intraperitoneal adhesion formation in rats by icodextrin at a range of concentrations. Gynecologic Oncology 88:3, 304-308
CrossRef289
Eelco de Bree, Hilde Rosing, Jos H. Beijnen, John Romanos, John Michalakis, Vasilis Georgoulias, Dimitris D. Tsiftsis. (2003) Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anti-Cancer Drugs 14:2, 103-110
CrossRef290
Anna Stevenson, Martin Gore. (2003) Specific Keynote: Clinical Trial Design Problems in Ovarian Cancer. Gynecologic Oncology 88:1, S117-S121
CrossRef291
Debra Hawes, P.Y. Liu, Franco M. Muggia, Sharon Wilczynski, Richard Cote, Juan Felix, Keith Terada, Robert J. Belt, David S. Alberts. (2002) Correlation of p53 Immunostaining in Primary and Residual Ovarian Cancer at the Time of Positive Second-Look Laparotomy and its Prognostic Role: A Southwest Oncology Group Ancillary Study. Gynecologic Oncology 87:1, 17-23
CrossRef292
David Heddens, David S. Alberts, Edward V. Hannigan, Steven D. Williams, Dava Garcia, Denise J. Roe, Jeffrey Bell, Ronald D. Alvarez. (2002) Prediction of the Need for Red Cell Transfusion in Newly Diagnosed Ovarian Cancer Patients Undergoing Platinum-Based Treatment. Gynecologic Oncology 86:3, 239-243
CrossRef293
Mark Harries, Martin Gore. (2002) Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosis. The Lancet Oncology 3:9, 529-536
CrossRef294
Franco M Muggia, Leonard Liebes, Maitreyee Hazarika, Scott Wadler, Anne Hamilton, Gila Hornreich, Joan Sorich, Chung Chiang, Elliot Newman, Milan Potmesil, Howard Hochster. (2002) Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days. Anti-Cancer Drugs 13:8, 819-825
CrossRef295
Maurie Markman, Barbara Kulp, Gertrude Peterson, Alexander Kennedy, Jerome Belinson. (2002) Second-Line Therapy of Ovarian Cancer with Paclitaxel Administered by Both the Intravenous and Intraperitoneal Routes: Rationale and Case Reports. Gynecologic Oncology 86:1, 95-98
CrossRef296
L.S. Hofstra, A.M.E. Bos, E.G.E. de Vries, A.G.J. van der Zee, A.T.M. Willemsen, H. Rosing, J.H. Beijnen, N.H. Mulder, J.G. Aalders, P.H.B. Willemse. (2002) Kinetic Modeling and Efficacy of Intraperitoneal Paclitaxel Combined with Intravenous Cyclophosphamide and Carboplatin as First-Line Treatment in Ovarian Cancer. Gynecologic Oncology 85:3, 517-523
CrossRef297
K. Fujiwara, S. Suzuki, E. Yoden, H. Ishikawa, Y. Imajo, I. Kohno. (2002) Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. International Journal of Gynecological Cancer 12:3, 250-256
CrossRef298
Alexander D Guminski, Paul R Harnett, Anna deFazio. (2002) Scientists and clinicians test their metal–back to the future with platinum compounds. The Lancet Oncology 3:5, 312-318
CrossRef299
Patrick Hwu, Ralph S. Freedman. (2002) The Immunotherapy of Patients With Ovarian Cancer. Journal of Immunotherapy 25:3, 189-201
CrossRef300
Prema P. Peethambaram, Harry J. Long. (2002) Second-line and subsequent therapy for ovarian carcinoma. Current Oncology Reports 4:2, 159-164
CrossRef301
Takashi Tamura, Fumiko Fujita, Masahiko Tanimoto, Masako Koike, Akira Suzuki, Masahide Fujita, Yuji Horikiri, Yasuo Sakamoto, Takehiko Suzuki, Hiroyuki Yoshino. (2002) Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice. Journal of Controlled Release 80:1-3, 295-307
CrossRef302
Allan Covens, Mark Carey, Peter Bryson, Shailendra Verma, Michael Fung Kee Fung, Mary Johnston. (2002) Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian Cancer. Gynecologic Oncology 85:1, 71-80
CrossRef303
Maurie Markman. (2002) Role of chemotherapy in the management of ovarian cancer. Expert Review of Anticancer Therapy 2:1, 90-96
CrossRef304
Carlo R. Rossi, Mirto Foletto, Simone Mocellin, Pierluigi Pilati, Michele De Simone, Marcello Deraco, Francesco Cavaliere, Pietro Palatini, Fabiola Guasti, Romano Scalerta, Mario Lise. (2002) Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis. Cancer 94:2, 492-499
CrossRef305
James M.G. Larkin, Martin E. Gore. (2002) Chemotherapy Options for Patients with Relapsed Epithelial Ovarian Cancer. American Journal of Cancer 1:3, 205-216
CrossRef306
Alfred T Culliford, Ari D. Brooks, Sunil Sharma, Leonard B. Saltz, Gary K. Schwartz, Eileen M. O’Reilly, David H. Ilson, Nancy E. Kemeny, David P. Kelsen, Jose G. Guillem, W Douglas Wong, Alfred M. Cohen, Philip B. Paty. (2001) Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. Annals of Surgical Oncology 8:10, 787-795
CrossRef307
Arjen J Witkamp, Eelco de Bree, R Van Goethem, Frans A.N Zoetmulder. (2001) Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treatment Reviews 27:6, 365-374
CrossRef308
D IM, W MCGUIRE, N ROSENSHEIN. (2001) CONTEMPORARY MANAGEMENT OF OVARIAN CANCER. Obstetrics and Gynecology Clinics of North America 28:4, 759-773
CrossRef309
Stefan Spörri, Vimlarani Chopra, Norman Egger, Hal K Hawkins, Massoud Motamedi, Ekkehard Dreher, Henning Schneider. (2001) Effects of 5-aminolaevulinic acid on human ovarian cancer cells and human vascular endothelial cells in vitro. Journal of Photochemistry and Photobiology B: Biology 64:1, 8-20
CrossRef310
Claire F. Verschraegen. (2001) Intracavitary therapies for mesothelioma. Current Treatment Options in Oncology 2:5, 385-394
CrossRef311
Mark Harries, Stanley B Kaye. (2001) Recent advances in the treatment of epithelial ovarian cancer. Expert Opinion on Investigational Drugs 10:9, 1715-1724
CrossRef312
Scott M. Eisenkop, Nick M. Spirtos. (2001) What Are the Current Surgical Objectives, Strategies, and Technical Capabilities of Gynecologic Oncologists Treating Advanced Epithelial Ovarian Cancer?. Gynecologic Oncology 82:3, 489-497
CrossRef313
Scott M. Eisenkop, Nick M. Spirtos. (2001) Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is There a Correlation with “Biological Aggressiveness” and Survival?. Gynecologic Oncology 82:3, 435-441
CrossRef314
Eugene Chang, H.Richard Alexander, Steven K Libutti, Ronald Hurst, Suoping Zhai, William D Figg, David L Bartlett. (2001) Laparoscopic continuous hyperthermic peritoneal perfusion11No competing interests declared.. Journal of the American College of Surgeons 193:2, 225-229
CrossRef315
Edward L Trimble, John Wright, Michaele C Christian. (2001) Treatment of platinum-resistant ovarian cancer. Expert Opinion on Pharmacotherapy 2:8, 1299-1306
CrossRef316
Mace L. Rothenberg, P.Y. Liu, Sharon Wilczynski, Edward V. Hannigan, Sheldon A. Weiner, Geoffrey R. Weiss, Verda J. Hunter, Julia A. Chapman, Amy Tiersten, Peter C. Kohler, David S. Alberts. (2001) Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women with Stage III Epithelial Ovarian Cancer: A Southwest Oncology Group Trial (SWOG-9326). Gynecologic Oncology 82:2, 317-322
CrossRef317
Scott M. Eisenkop, Nick M. Spirtos. (2001) The Clinical Significance of Occult Macroscopically Positive Retroperitoneal Nodes in Patients with Epithelial Ovarian Cancer. Gynecologic Oncology 82:1, 143-149
CrossRef318
P. F. Conte, A. Gadducci, C. Cianci. (2001) Second-line treatment and consolidation therapies in advanced ovarian cancer. International Journal of Gynecological Cancer 11:s1, 52-56
CrossRef319
Agustin A Garcia, Franco M Muggia, C Paul Spears, Susan Jeffers, Howard Silberman, Mahesh Pujari, Robert T Koda. (2001) Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2′-deoxyuridine and leucovorin. Anti-Cancer Drugs 12:6, 505-511
CrossRef320
Maurie Markman. (2001) Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. Critical Reviews in Oncology/Hematology 38:3, 171-175
CrossRef321
Martee L. Hensley, Dore Lebeau, L.F. Leon, E. Venkatraman, Roger Waltzman, Paul Sabbatini, Lois Almadrones, Dennis Chi, David Spriggs. (2001) Identification of Risk Factors for Requiring Transfusion during Front-Line Chemotherapy for Ovarian Cancer. Gynecologic Oncology 81:3, 485-489
CrossRef322
Scott Wadler. (2001) New developments in the treatment of ovarian cancer. Expert Opinion on Investigational Drugs 10:6, 1167-1172
CrossRef323
Maurie Markman. (2001) Intraperitoneal chemotherapy in the management of malignant disease. Expert Review of Anticancer Therapy 1:1, 142-148
CrossRef324
S. Makhija, M. Leitao, P. Sabbatini, N. Bellin, L. Almadrones, L. Leon, D.R. Spriggs, R. Barakat. (2001) Complications Associated with Intraperitoneal Chemotherapy Catheters. Gynecologic Oncology 81:1, 77-81
CrossRef325
J. Christian, H. Thomas. (2001) Ovarian cancer chemotherapy. Cancer Treatment Reviews 27:2, 99-109
CrossRef326
P. Pilati, C.R. Rossi, S. Mocellin, M. Foletto, B. Scagnet, L. Pasetto, M. Lise. (2001) Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. European Journal of Surgical Oncology (EJSO) 27:2, 125-134
CrossRef327
Gamal H Eltabbakh, Christopher S Awtrey. (2001) Current treatment for ovarian cancer. Expert Opinion on Pharmacotherapy 2:1, 109-124
CrossRef328
David D. Gibbs, Martin E. Gore. (2001) Pursuit of Optimum Outcomes in Ovarian Cancer. Drugs 61:8, 1103-1120
CrossRef329
Maurie Markman. (2001) Intraperitoneal Drug Delivery of Antineoplastics. Drugs 61:8, 1057-1065
CrossRef330
FRANCO MUGGIA, LEONARD LIEBES, MILAN POTMESIL, ANNE HAMILTON, HOWARD HOCHSTER, GILA HORNREICH, JOAN SORICH, ANDREA DOWNEY, HEATHER WASSERSTROM. (2000) Intraperitoneal Topoisomerase-I Inhibitors: Preliminary Findings with 9-Aminocamptothecin. Annals of the New York Academy of Sciences 922:1, 178-187
CrossRef331
Noriaki Sakuragi, Ayako Nakajima, Eiji Nomura, Noriko Noro, Hideto Yamada, Ritsu Yamamoto, Seiichiro Fujimoto. (2000) Complications Relating to Intraperitoneal Administration of Cisplatin or Carboplatin for Ovarian Carcinoma. Gynecologic Oncology 79:3, 420-423
CrossRef332
Hiroshi Yamaguchi, Masazumi Ito, Nagayasu Toyoda. (2000) Real-Time Ultrasonographically Guided Transvaginal Instillation for Intraperitoneal Chemotherapy of Ovarian Carcinoma. Gynecologic Oncology 79:2, 332-335
CrossRef333
R.T Liggins, S D'Amours, J.S Demetrick, L.S Machan, H.M Burt. (2000) Paclitaxel loaded poly(l-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill. Biomaterials 21:19, 1959-1969
CrossRef334
Y Rey, J Porcheron, J.N Talabard, K Szafnicki, J.G Balique. (2000) Carcinoses péritonéales traitées par chirurgie de réduction tumorale et chimiohyperthermie intrapéritonéale. Annales de Chirurgie 125:7, 631-642
CrossRef335
Donald E. Marsden, Michael Friedlander, Neville F. Hacker. (2000) Current management of epithelial ovarian carcinoma: A review. Seminars in Surgical Oncology 19:1, 11-19
CrossRef336
Erkan Topuz, Yavuz Salihoglu, Adnan Aydiner, P?nar Saip, Faruk Tas, Tamer Sozen, Sinan Berkman, Ergin Bengisu. (2000) Celsite
port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. Journal of Surgical Oncology 74:3, 223-226
CrossRef337
Farid Fata, Ilan G. Ron, Fernando Maluf, David Klimstra, Nancy Kemeny. (2000) Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines. Cancer 88:11, 2447-2451
CrossRef338
Robert J. Morgan, Patricia Braly, Lucille Leong, Stephen Shibata, Kim Margolin, George Somlo, Mark McNamara, Jeff Longmate, Stanley Schinke, James Raschko, Stuart Nagasawa, Neil Kogut, Letitia Najera, Dina Johnson, James H. Doroshow. (2000) Phase II Trial of Combination Intraperitoneal Cisplatin and 5-Fluorouracil in Previously Treated Patients with Advanced Ovarian Cancer: Long-Term Follow-up. Gynecologic Oncology 77:3, 433-438
CrossRef339
L.S. Hofstra, E.G.E.de Vries, N.H. Mulder, P.H.B. Willemse. (2000) Intraperitoneal chemotherapy in ovarian cancer. Cancer Treatment Reviews 26:2, 133-143
CrossRef340
J. B. Vermorken. (2000) The role of intraperitoneal chemotherapy in epithelial ovarian cancer. International Journal of Gynecological Cancer 10:s1, 26-32
CrossRef341
Giuseppe Giaccone. (2000) Clinical Perspectives on Platinum Resistance. Drugs 59:Supplement 4, 9-17
CrossRef342
A. A. Epenetos, V. Hird, H. Lambert, P. Mason, C. Coulter. (2000) Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. International Journal of Gynecological Cancer 10:s1, 44-46
CrossRef343
A. Poveda. (2000) Advanced ovarian cancer: update, remarks and conclusions on optimal therapy. International Journal of Gynecological Cancer 10:s1, 57-60
CrossRef344
M. A. Reymond, B. Hu, A. Garcia, T. Reck, F. Köckerling, J. Hess, P. Morel. (2000) Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surgical Endoscopy 14:1, 51-55
CrossRef345
Peter J. O??Dwyer, James P. Stevenson, Steven W. Johnson. (2000) Clinical Pharmacokinetics and Administration of Established Platinum Drugs. Drugs 59:Supplement 4, 19-27
CrossRef346
Giorgio Cocconi, Mariangela Bella, Renata Lottici, Francesco Leonardi, Guido Ceci, Rodolfo Passalacqua, Beatrice Di Blasio, Cesare Bordi, Bruno Biscottini, Mauro Melpignano, Danilo De Biasi, Cecilia Finardi, Marisa Bacchi. (1999) Mature Results of a Prospective Randomized Trial Comparing a Three-Weekly with an Accelerated Weekly Schedule of Cisplatin in Advanced Ovarian Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials 22:6, 559
CrossRef347
N Colombo. (1999) Role of chemotherapy in relapsed ovarian cancer. Critical Reviews in Oncology/Hematology 32:3, 221-228
CrossRef348
Robert J. Morgan, Patricia Braly, Gary Cecchi, Lucille Leong, Stephen Shibata, Kim Margolin, George Somlo, Mark McNamara, Jeff Longmate, Stanley Schinke, James Raschko, Stuart Nagasawa, Neil Kogut, Pablo Parker, Anthony Stein, Jonathan Cho, Eileen Smith, Paul Coluzzi, Leticia Najera, Dina Johnson, Eleanor Womack, James H. Doroshow. (1999) Phase II Trial of Intraperitoneal Cisplatin with Intravenous Doxorubicin and Cyclophosphamide in Previously Untreated Patients with Advanced Ovarian Cancer—Long-Term Follow-Up. Gynecologic Oncology 75:3, 419-426
CrossRef349
J. E. Groopman, L. M. Itri. (1999) Chemotherapy-Induced Anemia in Adults: Incidence and Treatment. JNCI Journal of the National Cancer Institute 91:19, 1616-1634
CrossRef350
Jonathan S. Berek, Maurie Markman, Bette Stonebraker, Samuel S. Lentz, Mark D. Adelson, Koen DeGeest, David Moore. (1999) Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study. Gynecologic Oncology 75:1, 10-14
CrossRef351
Vincent E. Herrin, J. Tate Thigpen. (1999) Chemotherapy for ovarian cancer: Current concepts. Seminars in Surgical Oncology 17:3, 181-188
CrossRef352
Laurie A. Rund, Bryan K. Cho, Thomas C. Manning, Phillip D. Holler, Edward J. Roy, David M. Kranz. (1999) Bispecific agents target endogenous murine T cells against human tumor xenografts. International Journal of Cancer 83:1, 141-149
CrossRef353
P.F Conte, C Cianci, A Gadducci. (1999) Up date in the management of advanced ovarian carcinoma. Critical Reviews in Oncology/Hematology 32:1, 49-58
CrossRef354
Karin S. Kapp, Daniel S. Kapp, Johann Poschauko, Georg F. Stücklschweiger, Arnulf Hackl, Helmuth Pickel, Edgar Petru, Raimund Winter. (1999) The Prognostic Significance of Peritoneal Seeding and Size of Postsurgical Residual in Patients with Stage III Epithelial Ovarian Cancer Treated with Surgery, Chemotherapy, and High-Dose Radiotherapy. Gynecologic Oncology 74:3, 400-407
CrossRef355
P Liu. (1999) False Positive Rates of Randomized Phase II Designs. Controlled Clinical Trials 20:4, 343-352
CrossRef356
M Markman. (1999) Intraperitoneal chemotherapy. Critical Reviews in Oncology/Hematology 31:3, 239-246
CrossRef357
Nicholas Lambrou, Edward L. Trimble. (1999) Dose-intensive approaches to ovarian cancer. Current Oncology Reports 1:1, 54-58
CrossRef358
Sharmila Makhija, Paul Sabbatini, Richard R. Barakat. (1999) Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Current Opinion in Obstetrics and Gynaecology 11:1, 23-27
CrossRef359
K. Fujiwara, H. Yamauchi, T. Yoshida, I. Kohno. (1998) Relationship between calculated carboplatin area under the curve, using the Cockcroft-Calvert formula and the Chatelut formula, and thrombocytopenia induced by intraperitoneal carboplatin in combination with intravenous cyclophosphamide. International Journal Of Clinical Oncology 3:5, 304-310
CrossRef360
Keiichi Fujiwara, Hideaki Yamauchi, Takashi Yoshida, Sachiko Suzuki, Takashi Oda, I. Kohno. (1998) Relationship between Peritoneal Washing Cytology through Implantable Port System (IPS-Cytology) and Second-Look Laparotomy in Ovarian Cancer Patients with Unmeasurable Residual Diseases. Gynecologic Oncology 70:2, 231-235
CrossRef361
William P. McGuire. (1998) High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors. Current Problems in Cancer 22:3, 138-177
CrossRef362
Michael F. Flessner, Robert L. Dedrick. (1998) Tissue-level transport mechanisms of intraperitoneally-administered monoclonal antibodies. Journal of Controlled Release 53:1-3, 69-75
CrossRef363
Fernando O. Recio, M.Steven Piver, Ronald E. Hempling, Deborah L. Driscoll. (1998) Five-Year Survival after Second-Line Cisplatin-Based Intraperitoneal Chemotherapy for Advanced Ovarian Cancer. Gynecologic Oncology 68:3, 267-273
CrossRef364
David A. Solomon, Gabor I. Keitner, Christine E. Ryan, Ivan W. Miller. (1998) Lithium Plus Valproate as Maintenance Polypharmacy for Patients With Bipolar I Disorder. Journal of Clinical Psychopharmacology 18:1, 38-49
CrossRef365
Ivor Benjamin, Stephen C. Rubin. (1998) Modern treatment options in epithelial ovarian carcinoma. Current Opinion in Obstetrics and Gynaecology 10:1, 29-32
CrossRef366
(1997) Treatment of Ovarian Cancer with Intraperitoneal Cisplatin. New England Journal of Medicine 336:23, 1674-1675
Full Text367
Herbert M Pinedo, Giuseppe Giaccone. (1997) Chemotherapy. The Lancet 349, S7-S9
CrossRef
- Letters
